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The JAK-STAT pathway is a major signaling pathway involved in many biological 
processes including proliferation, apoptosis, and differentiation.  Aberrant 
expression of STATs has been reported in multiple human cancers and murine 
mouse models of tumorigenesis.  Previous studies from our lab and others have 
established a critical role for Stat3 in epithelial tumorigenesis, but the role of 
Stat1 is largely unknown.  The current study was designed to explore the role of 
Stat1 during multistage skin carcinogenesis.  Topical treatment with both TPA 
and the anthrone derivative chrysarobin (CHRY) led to rapid phosphorylation of 
Stat1 on both tyrosine (Tyr701) and serine (Ser727) residues in epidermis. 
CHRY treatment also led to upregulation of unphosphorylated Stat1 (uStat1) at 
later time points.  In addition, CHRY treatment also led to upregulation of IRF-1 
mRNA and protein which was dependent on Stat1.  Further analyses 
demonstrated that topical treatment with CHRY but not TPA upregulated 
interferon-gamma (IFNγ) mRNA in the epidermis and that the induction of both 
IRF-1 and uStat1 was dependent on IFNγ signaling.  Stat1 deficient (Stat1-/-) 
mice were highly resistant to skin tumor promotion by CHRY.  In contrast, the 
tumor response (in terms of both papillomas and squamous cell carcinomas) was 
similar in Stat1-/- mice and wild-type littermates with TPA as the promoter.  
Histological evaluation of the proliferative response confirmed the data obtained 
 vii 
from the tumor study for both TPA and CHRY.  In addition, maximal induction of 
both cyclooxygenase-2 and inducible nitric oxide synthase in epidermis following 
treatment with CHRY was also dependent on the presence of functional Stat1. 
Following CHRY treatment, Stat1-/- mice exhibited reduced macrophage 
infiltration and reduced production of many immune cell derived 
chemokines/cytokines. These studies define a novel mechanism associated with 
skin tumor promotion by the anthrone class of tumor promoters involving 
upregulation of IFNγ signaling in the epidermis and downstream signaling 
through activated (phosphorylated) Stat1 and subsequent upregulation of IRF-1 
and uStat1.   
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Chapter 1: Introduction 
1.1 Signal Transducer and Activators of Transcription 
Signal Transducers and Activators of Transcription (STATs) represent a family 
of conserved transcription factors that transduce extracellular signals from the cellular 
membrane of the cell to the nucleus.  These latent cytoplasmic transcription factors 
consist of seven members: Stat1α/β, Stat2, Stat3α/β, Stat 4, Stat5A, Stat5B and Stat6, 
7(1). STATs can generally be classified into two groups according to their function. One 
group consists of Stat2, Stat4 and Stat6, which are activated by various cytokines and 
play distinct roles in T-cell development and interferon signaling.  The other group 
includes Stat1, Stat3 and Stat5, which regulate important aspects of cellular growth, 
proliferation and apoptosis (2). 
Our understanding of STAT signaling began over 40 years ago when Alick 
Isaacs and Jean Lindenmann et al reported on a phenomenon in the field of ‘‘virus 
interference,’’ that described a condition that disrupted virus formation (3) (4).  Over the 
years the understanding of this pathway has grown to encompass all aspects of its 
function and can be seen in the nomenclature itself. The aptly named STATs represent 
a class of molecules with dual functionality. Stat proteins not only provide a means to 
transmit signals from the exterior of the cell to the nucleus but they also directly 
participate in gene regulation by binding to DNA.   
1.2 Structure of STATs 
STATs are proteins composed of approximately 850 amino acids, with the 
exception of Stat2 and Stat6, which have between 750 and 800 amino acids and range 
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in size from 90-115kDA (5).  STATs share several highly conserved domains, which 
are important for their respective functions. STATs contain an N-terminal 
oligomerization domain, which is involved in stabilizing protein-protein interactions. This 
domain is also responsible for dimer-dimer interactions that facilitate the formation of 
STAT tetramers or oligomers.  STATs contain a DNA-binding domain (DBD) that 
confers specificity of binding to cognate DNA sequences of target gene promoters.  A 
linker domain resides between the DBD and the SRC homology-2 (SH2) domain.  The 
function of this domain has not been fully characterized, although mutations within this 
domain affect the stability of DNA binding (6).  The SH2 domain contains the critical 
tyrosine residues (Y701 for Stat1, Y690 for Stat2, Y705 for Stat3, Y693 for Stat4, Y695 
for Stat5, and Y641 for Stat6) that are required for Stat recruitment to the cytoplasmic 
tail of the phosphorylated receptor.  Phosphorylation of this site leads to activation 
(dimerization) of STATs.  Differences in the SH2 domain confer selectivity to different 
cytokine receptors of each respective STAT protein [reviewed in (7)].  The 
transactivation domain (TAD) of each STAT is located in the carboxyl terminal region. 
The TAD domains contain the serine phosphorylation site that is responsible for 
maximal transcriptional activation (Bowman Oncogene 2000).   Some STATs, in 
particular Stat1 and Stat3, have naturally occurring splice variants (Stat1β and Stat3β), 
which lack a portion of the C-terminal transactivation domain. These variants can 
potentially act as dominant-negative forms (8, 9).  Figure 1 shows the structure of a 
representative STAT (Stat1) dimer bound to DNA (panel a) as well as a diagram of the 
various structural domains (panel b). 
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Figure 1.  The Core Structure of a STAT1 Dimer Bound to DNA.  
(a) The core structure (amino acids 130–712) shows binding of a 
STAT1 dimer to DNA and the location of binding sites of various 
proteins in various domains.  STATs share several highly conserved 
domains that are important for their respective function.  (b) STATs 
contain an N-terminal domain (N-terminus), a Coiled-Coiled domain  
(CC), a DNA-binding Domain (DBD), a Linker Domain, a Src-
Homology-2 domain (SH2 Domain) and a transactivation domain 
(TAD). Reproduced with the permission of the journal Nature 
Reviews: Molecular Cell Biology. Levy DE and Darnell JE Jr. 
(2002)“Stats: transcriptional control and biological impact.”Nature 
Reviews Molecular Cell Biology 3, 651-662.  
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1.3 Activation of STATs 
STATs are activated by a variety of stimuli, including cytokines, growth factors, 
and hormones.   Cytokines represent a large number of soluble molecules that regulate 
cellular growth, differentiation, and immune responses. Cytokines are classified as 
Type I (i.e. IL-2, IL-3, IL-4) and Type II (interferons and IL-10) and signal via cytokine 
receptors that contain no intrinsic enzymatic kinase activity, but accomplish 
phosphorylation of STATs via receptor associated Janus Kinases (JAKs).  The JAK 
family of receptor associated tyrosine kinases consist of four members: JAK1, JAK2, 
JAK3, and tyrosine kinase 2 (Tyk2), which are activated by receptor dimerization after 
ligand binding (10).   
STATs are also activated by growth factor receptors such as epidermal growth 
factor (EGF) receptor, insulin-like growth factor (IGF)-1 receptor, platelet-derived 
growth factor (PDGF) receptor, hepatocyte growth factor (HGF) receptor, and colony-
stimulating factor- 1 (CSF-1) receptor, all of which possess an intrinsic tyrosine kinase 
activity (11).  In addition to cytokine and growth factor receptor activation, STATs can 
also be activated by non-receptor tyrosine kinases such as SRC and ABL. STATs can 
also be activated by seven transmembrane domain receptors, such as angiostatin II, 
serotonin and α-melatonin (12). 
Following ligand binding, a conformational change occurs on the cytoplasmic tail 
of the receptor inducing autophosphorylation and transphosphorylation of the 
associated JAK.  This is followed by phosphorylation of the cytoplasmic tail of the 
receptor, which provides docking sites for the recruitment of STAT molecules that 
recognize phosphotyrosine via their phosphotyrosine binding domain (PTB) or SH2 
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domain (13).  Once recruited to the SH2 domain of the receptor the STAT molecules 
are subsequently phosphorylated on tyrosine residues (14). Tyrosine phosphorylated 
STATs subsequently form homo/hetero dimers or heterotrimeric complexes that 
translocate to the nucleus where they bind to cognate DNA sequences and activate 
gene transcription.  Figure 2 is a schematic depicting activation of STATs via receptors 
such as growth factor receptors, cytokine receptors and G-protein coupled receptors.    
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Figure 2.  Activation of the JAK-STAT Pathway via Receptor 
Signaling.  A conceptual diagram of the multiple mechanisms for 
tyrosine phosphorylation of STATs by Janus kinases (JAKs) or other 
protein tyrosine kinases (PTKs) that are intrinsic to receptors or that 
are present in the cytoplasm or nucleus. Tyrosine phosphorylation 
generates STAT dimers that can bind specific DNA targets.  The 
JAK-STAT pathway is activated by a variety of stimuli.  STATs can 
be activated by growth factor receptors that possess intrinsic kinase 
activity. They may also be activated by cytokine receptors which 
employ the use of a family of receptor associated kinases called 
Jaks (Jak1, Jak2, Jak2, Tyk2).  STATs may also be activated by 
non-receptor tyrosine kinases such as Src and ABL.  Reproduced 
with the permission of the journal Nature Reviews: Immunology.  
Reich NC and Liu L. (2006) “Tracking STAT nuclear traffic.” Nature 
Reviews Immunology 6, 602-612.  
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Previous studies also reported that STATs undergo cycles of activation-
inactivation.  STAT activity is coupled with nuclear-cytoplasmic shuttling and regulated 
by posttranslational modifications such as phosphorylation and acetylation.  Nuclear 
retention of STATs is dependent upon their phosphorylation status.  For example, 
phosphorylation of Stat1 on tyrosine 701 results in nuclear translocation, whereas 
acetylation of lysine residues 410 and 413 leads to increased dephosphorylation.  Thus, 
acetylation results in Stat1 inactivation (15).  After binding to DNA and activating gene 
transcription, STAT inactivation occurs rapidly and the unphosphorylated STAT 
molecule is exported out of the nucleus. 
1.4 Negative Control of STATs 
STAT activation is a transient process. Within hours the activating signals 
subside and STATs are again in an inactive state. The JAK-STAT signaling pathway is 
negatively regulated by two nuclear regulators, protein inhibitors of activated STATs 
(PIAS) and protein tyrosine phosphatases (PTPs) and one cytoplasmic regulator, 
suppressor of cytokine signaling (SOCS). There is data to suggest that PTPs also act 
at the membrane level by dephosphorylating activated JAKs at the receptor.  PIAS 
interact exclusively with tyrosine-phosphorylated forms of Stat proteins, thereby 
preventing DNA binding.  PTPs, which contain SH2 domains, negatively regulate 
activated STATs by interacting and directly dephosphorylating STATs in the nucleus. 
SOCS are cytokine-induced proteins that are recruited to activated receptor complexes 
to regulate signaling. SOCS proteins inhibit signaling by directly binding to activated 
JAKS, thereby competing for STAT binding and/or by targeting activated JAKs for 
ubiquitin-mediated proteasomal degradation (16).  Figure 3 shows the major pathways 
involved in negative regulation of STAT signaling.  
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Figure 3.  Negative Regulators of STAT Signaling. Stat activation 
is a transient process and therefore requires negative regulation. 
The Janus kinase (JAK)–signal transducer and activator of 
transcription (STAT) pathway is regulated at many levels. Two 
nuclear regulators, protein inhibitors of activated STATs (PIAS), 
protein tyrosine phosphatases (PTP) and one cytoplasmic regulator, 
suppressor of cytokine signaling (SOCS), negatively regulate the 
JAK-STAT signaling pathway.  PIAS bind directly to activated 
STATs whereby they block the transcription of downstream target 
genes.  PTP dephosphorylate activated STATs thereby facilitating 
their export out of the nucleus. The SOCS class of proteins acts in a 
classical negative feedback loop. They are transcriptionally 
upregulated after JAK-STAT pathway activation. SOCS negatively 
regulate STAT signaling by binding to activated JAKS, thereby 
blocking JAK activity.  Reproduced with the permission of the journal 
Nature Reviews: Immunology.  Shuai K, and Liu B. (2003) 
“Regulation of JAK-STAT signaling in the immune system.”Nature 
Reviews Immunology 3, 900-911.  
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1.5 Interferon Signaling 
Isaacs and Lindenmann identified interferon (IFN), the first cytokine discovered, 
during their seminal studies over 50 years ago (3, 4). IFNs are a family of multi-
functional proteins that were first discovered due to their ability to interfere with viral 
replication.  IFNs are historically classified as Type I and Type II, based on receptor 
specificity and sequence homology. Type I IFNs are comprised of multiple interferon-
alpha (α) subtypes (14-20 depending species), interferon beta (β), interferon omega (ω) 
and interferon tau (τ).  All Type I IFNs are structurally related and bind to a 
heterodimeric receptor, IFNAR (comprised of IFNAR1 and IFNAR2). 
Type II IFNs are represented by only one cytokine, which is IFN gamma 
(γ)(IFNγ). IFNγ binds to a different receptor than that of Type I IFNs.   The IFNγR is 
comprised of two ligand-binding IFNγR1 chains that are associated with two signal-
transducing IFNγR2 chains (17).  IFN receptors, like other cytokine receptors, possess 
no intrinsic kinase activity and therefore depend on receptor-associated kinases to 
phosphorylate their substrates.   IFNs also employ JAK family tyrosine kinases as 
described above (17).   
Binding of the Type I IFNs, such as IFNα, to its receptor induces dimerization of 
the two subunits and leads to the auto and transphosphorylation of TYK2 and Jak1.  
Activated JAKs then phosphorylate the receptor cytoplasmic domain on tyrosine 
residues, which provides a docking site for Stat1 or Stat2. Stat1 or Stat2 is then able to 
bind and is subsequently phosphorylated on tyrosine (Y701 for Stat1; Y690 for Stat2) 
by JAKs, which in turn allows the recruitment of Stat1. Stat1 is subsequently 
phosphorylated on tyrosine, which allows the release of Stat1/Stat2 heterodimer.  The 
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Stat1/Stat2 heterodimer is now available to form a heterotrimeric complex containing 
p48 (also known as ISGF3 or IRF9), thus forming the ISGF3 complex. The ISGF3 
transcription factor complex translocates to the nucleus where it binds to DNA 
containing the ISRE (IFNα-stimulated gene response element) sequence in the 
promoter region of its target genes(18) 
Upon binding of IFNγ to its receptor, IFNγR1 and IFNγR2 dimerize which leads to 
the auto and transphosphorylation of JAK1 and JAK2. The JAKs in turn cause the 
phosphorylation of the cytoplasmic domain of the IFNγR1 tail, which provides SH2 
docking sites for STAT1. Once phosphorylated, Stat1 homodimers translocate to the 
nucleus and bind to DNA containing the GAS (IFNγ-activated site) sequences.  Figure 
4 illustrates the canonical signaling pathways for both Type I and Type II IFNs. 
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Figure 4.  Interferon Receptor Activation by Classical JAK-STAT 
signaling.  IFNs are historically classified as Type I and Type II, which is 
based on receptor specificity and sequence homology. Type I IFNs are 
comprised of multiple interferon-alpha (α) subtypes, interferon beta (β), 
interferon omega (ω), and interferon tau (τ).  Type II IFNs are represented 
by only one cytokine, IFNγ. JAK1 and TYK2 activation is associated with 
the type I IFN receptor activation. Which results in tyrosine phosphorylation 
of STAT2 (signal transducer and activator of transcription 2) and STAT1; 
which results in the formation of STAT1–STAT2–IRF9 (IFN-regulatory 
factor 9) complexes.  IFNs also induce the formation of Stat1 homodimers 
that bind to IFN-gamma activated sequences (GAS) elements located in 
the promoter region ISGs, thereby initiating the transcription of these 
genes. Reproduced with the permission of the journal Nature Reviews: 
Immunology.  Platanias LC. (2005) “Mechanisms of type-I- and type-II-
interferon-mediated signaling.” Nature Reviews Immunology 5, 375-386.  
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1.6 Stat1 and Immune Function 
Stat1 was the first member of the STAT family of proteins discovered.  Stat1 has 
been shown to be the principal transducer of Type I (α and β) and Type II (γ) IFNs. The 
IFNγ/Stat1 axis has been shown to regulate many biological processes such as cellular 
growth, immune response, and even inflammation [reviewed in (5)].  Type I and Type II 
IFNs play a complementary and non-redundant role in defense against a broad 
spectrum of viral and bacterial pathogens.  IFNs play a vital role in both the innate and 
humoral immune response.  Various immunocytes such as lymphocytes, dendritic cells 
and macrophages produce IFNs in response to invading pathogens (19).  
Activation of the IFNγ/Stat1 pathway is critical to processing and presentation of 
tumor antigens.   Stat1 regulates key components of the immunoediting machinery 
such as major histocompatibility complex (MHC) class I and II (20).  MHC class 
proteins are necessary for immune cells such as lymphocytes to display phagocytosed 
tumor antigens on their cell surface.  Dysregulation of Stat1-dependent expression of 
MHC and other components such as the MHC class II transactivator CIITA, leads to 
defective antigen presentation (21).  
1.7 Stat1 and Growth Arrest/Growth Inhibition  
Stat1 also plays a role in cellular growth, as its activation generally evokes an 
anti-proliferative program.  Stat1 has the ability to regulate the cell cycle at various 
points of its progression.  Previous reports have shown that Stat1 activation may inhibit 
cell cycle progression by blocking oncogenic signals such as c-Myc and various cyclins 
(A, B, D2, D3 and E) (22).  Stat1 has also been shown to negatively affect the cell cycle 
by up-regulating various tumor suppressor proteins, such as the cyclin-dependent 
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kinase inhibitors (CKIs), p21 WAF1/CIP1 and p27/KIP1 [reviewed in(23)].  The 
activation of these CKIs ultimately leads to G0/G1 cell cycle arrest.  In the prostatic 
cancer cell lines DU145, LNCaP, and PC-3 it was reported that treatment with IFNγ 
resulted in the down-regulation of the proto-oncogene (Her)-2/neu, which was shown to 
be Stat1-dependent (24).  
1. 8 Stat1 and Apoptosis 
The importance of Stat1 in the apoptotic response has been supported by the 
fact that pro-apoptotic properties of IFNs are largely mediated by STAT signaling.   
Stat1 has the ability to promote apoptosis by regulating both transcription-dependent 
and independent mechanisms.  Stat1 promotes apoptosis by inducing both initiator and 
effector caspases. Stat1 can induce the expression of caspases 1 and 11, which are 
required for activation of the effector caspases, 3 and 7, (25, 26). Activation of Stat1 via 
IFNγ signaling induces the expression of several surface cell death receptors and their 
ligands, such as Fas/FasL, TRAIL and its receptor Killer/DR5, (27-29).  Stat1 can also 
regulate other pro-apoptotic genes such as XIAP-associated factor- (XAF)-1, (30) and 
IFN-induced transmembrane protein 1 (IFITM1), (31).  It is noteworthy that Stat1 can 
also negatively regulate the expression of pro-survival genes such as Bcl-2 and Bcl-xl 
(32).  
Stat1 can serve as a co-activator of pro-apoptotic signaling.  In this regard, Stat1 acts 
as a co-activator by interacting with tumor necrosis factor (TNF)-α receptor 1 (TNFR1) 
and TNFR1-associated death domain protein (TRADD).  Acting as a component in this 
complex, Stat1 serves to inhibit NF-κB-mediated pro-survival signaling (33).  Stat1 is 
required for DNA damage-induced apoptosis through its direct interaction with p53 (34). 
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In addition Stat1 can also act on the negative regulator of p53, Mdm2, by targeting it for 
proteosomal degradation (34).  
1.9 Stat1 and Angiogenesis 
Angiogenesis plays an important role in the development of cancer (35).  
Neovascularization is vital to the progression of tumor development, and may also 
serve as a prognostic indicator of metastatic potential.  Stat1 has been shown to inhibit 
vascular endothelial growth factor (VEGF), a potent signaling molecule that promotes 
the formation of new blood vessels to tissues with inadequate oxygen supply.  Stat1 
inhibits the action of VEGF by inhibiting factors required for VEGF-induced tube 
formation, including urokinase plasminogen activator, angiopoetin-2, tissue inhibitor of 
matrix metalloproteinase (TIMP)-1, and VEGFR-2 (36).  In addition, Stat1 can activate 
the production of the CXC chemokine family member, interferon-inducible protein IP10 
(CXCL10). IP-10, a known anti-angiogenic gene, blocks the production of fibroblast 
growth factor (FGF)-β, (37) and inhibits endothelial cell motility (38). Endothelial cell 
motility is a critical component of the angiogenic response. 
 
1.10 Potential Role of Unphosphorylated Stat1 (uStat1) 
Recently, it has been found that Stats 1 and 3 (and possibly other Stats) may 
play important roles in mediating gene expression in the absence of tyrosine 
phosphorylation (39, 40).  Stat1 and Stat3 genes are targets of activated 
(phosphorylated) Stat1 and Stat3 proteins, respectively (41).  As a result, cytokine 
activation of Stat1 or Stat3 (e.g., IFNγ or IL-6, respectively), leads to the induction and 
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accumulation of uStats 1 and 3, which may persist for days after p-Stat levels have 
subsided (40).  In addition, induction of the Stat1 target gene, IRF-1, aids in the 
continued accumulation of uStat1 in response to IFNγ.  It is well-documented that 
uStats 1 and 3 can act as transcription factors to regulate a subset of genes that are 
different from those regulated by p-STATs (31, 39, 42). Together these data suggest 
that uStat1 may be transcriptionally active and may play a significant role in various 
cellular responses.  Transcriptional profiling has shown that the majority of uStat1 
target genes are antiviral immune response genes, however, uStat1 also induces a 
subset of genes implicated in radio- and chemo-resistance in cancer cells (42) (43). 
Disruption of IFN effector molecule 8 (IRF8) in soft tissue sarcoma cells leads to the 
accumulation of uStat1 (44) and promotes sarcoma cell metastasis by regulating gene 
transcription of apoptosis regulators Fas and Bad (44).  Overall, the role and 
mechanism(s) by which uStat1 mediate cellular responses and possible pro-
tumorigenic effects are largely unknown.  
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1.11 Evidence for a Pro-Tumorigenic Role of Stat1 
As previously stated, Stat1 is widely considered to possess tumor suppressive 
properties. There is emerging data that Stat1 may influence tumorigenesis by 
modulating several different aspects of tumor development.  Utilizing large-scale gene 
expression studies from melanoma patients, Stat1 was shown to be elevated at the 
peripheral edge (invasion front) compared to central areas of the tumor.  In addition, 
stable knockdown of Stat1 in metastatic melanoma cells significantly impaired their 
migratory and invasive capacity in matrigel and wounding assays (45).   
Stat1 may also influence tumorigenesis by suppressing the apoptotic response 
although in many instances Stat1 has a pro-apoptotic function.  For example, 
overexpression or constitutive activation of Stat1 may provide resistance to genotoxic 
stress including chemotherapy and ionizing radiation (IR).  Utilizing a squamous cell 
carcinoma cell line (SCC61), which was serially passaged to create a radioresistant cell 
line (nu61), Khodarev et al reported that nu61 cells were unresponsive to cytotoxic 
signals by radiation or IFNs, but suppression of Stat1 by short hairpen RNA rendered 
nu61 cells radiosensitive to IR.  They proposed a model where transient induction of 
Stat1 activates cytotoxic genes, which results in cell death.  Overexpression of Stat1 
led to the suppression of the cytotoxic response and induced the expression of pro-
survival genes (MCL-1, IFITM1, and USP18) that render the cells resistant to apoptosis 
(46).  
As previously stated, Stat1 may also influence tumor development by regulating 
key components of the antigen presentation machinery, such as MHCI and II.  Kovacic 
et al found that Stat1 deficiency inhibited the development of leukemia in Stat1-/- mice 
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(47).  Loss of Stat1 resulted in low levels of MHC class I proteins, which apparently 
enabled efficient NK cell lysis, and enhanced tumor clearance.  These findings define 
Stat1 as a tumor promoter in terms of leukemia development, since the upregulation of 
MHC I provides a mechanism by which newly formed tumors escape elimination by 
immune surveillance.  
Over the years it has been suggested that Stat1 has a role in the induction of a 
pro-inflammatory signaling cascade.  Stat1 has been found to be associated with 
several human pathological conditions associated with chronic inflammation including 
rheumatoid arthritis (48), pulmonary fibrosis (49), and Alzheimer’s disease (50) .   Stat1 
influences the inflammatory response by inducing key components such iNOS (51) and 
IRF-1 (52).  Utilizing models of inflammation-associated cancers, several groups have 
demonstrated the importance of Stat1 in inflammation.  Stat1 was shown to provide a 
pro-inflammatory signal in ConA-induced hepatitis by driving the expression of several 
chemoattractant chemokines via IRF-1 (53).  In addition, utilizing a model for gastric 
cancer, Ernest et al reported that loss of Stat1 reduced gastric cancer associated 
inflammation by reducing the pro-inflammatory interleukin, IL-11.  Collectively these 
findings demonstrate the complexity of Stat1 signaling, whereby Stat1 has a pro-
tumorigenic function by desensitizing cells to apoptosis, increasing metastatic potential, 
decreasing host recognition capacity and increasing the pro-inflammatory program. 
Table 1 summarizes Stat1 responsive genes involved in the process of tumorigenesis. 
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Table 1. Summary of Stat1 responsive genes that are involved in the 
process of tumorigenesis  
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1.12 Multistage Epithelial Carcinogenesis in Mouse Skin 
Skin carcinogenesis in mice can be accomplished by utilizing either complete or 
initiation-promotion protocols (54). The complete carcinogenesis protocol involves the 
topical application of a single large dose or repeated applications of a smaller dose of a 
carcinogen [i.e. 7,12-Dimethylbenz(a)anthracene (DMBA), 3-methylcholanthrene 
(MCA)]. The initiation-promotion protocol involves the application of a single 
subcarcinogenic dose of a carcinogen followed by repeated applications of a tumor 
promoter.  This well-established protocol in mouse skin recapitulates many aspects of 
human epithelial cancer (54).  Cancer development is a complex process whereby a 
normal cell undergoes genetic alterations that results in an altered phenotype that is 
characterized by a selective growth advantage.  Multiple lines of evidence suggest that 
these alterations occur in a multi-step process (55).  The complete carcinogenesis 
model does not allow interpretation of different stages of the tumorigenic process, 
whereas the initiation-promotion protocol allows for observable delineation. In the 
initiation-promotion protocol three distinct mechanistic stages can be identified.  
Initiation involves a DNA damaging event leading to mutation(s) in critical target cells 
(i.e. stem cells).  Promotion involves increased proliferation and altered cell behavior, 
which allows for clonal expansion of initiated cells into clonal outgrowths called 
papillomas.  Finally, tumor progression is characterized by the conversion of papillomas 
to SCCs. 
The first stage in chemically induced skin carcinogenesis is referred to as 
“initiation” and involves a DNA damaging event to genes in epidermal keratinocytes. 
The most commonly used initiating agent is the polycyclic aromatic hydrocarbon (PAH), 
DMBA.  DMBA causes a specific A to T (182) transversion mutation in codon 61 of the 
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Hras1 gene, although Kras mutations have also been documented in lesions initiated 
with DMBA [reviewed in (54)].  Mice are treated topically with a sub-carcinogeneic dose 
of DMBA that primarily targets keratinocyte stem cells, which are found at the base of 
the epidermal proliferative units and in the bulge region of the hair follicle [reviewed in 
(54, 56)]. 
During the process of tumor promotion, initiated stem cells undergo clonal 
expansion. The promotion stage is characterized by repeated applications of chemical 
agents called tumor promoters (e.g. TPA, chrysarobin (CHRY), okadaic acid, and 
others) or wounding leading to sustained epidermal hyperplasia and epidermal 
proliferation.  Initiated stem cells that harbor Ras mutations are believed to have a 
selective growth advantage during tumor promoter-induced epidermal proliferation. 
Classical tumor promoters are not intrinsically mutagenic but alter the expression of 
genes that are associated with tissue remodeling, hyperplasia, and inflammation (57). 
Repeated exposure to a given tumor promoter may increase mitogenic factors, 
increase inflammatory mediators and inhibit anti-apoptotic molecules. The end result of 
the promotion stage is characterized by the development of pre-malignant outgrowths 
in the skin called papillomas.  
The progression stage of multistage carcinogenesis results in further genetic 
alterations such as loss of heterozygosity, aneuploidy and trisomy leading to the 
conversion of pre-malignant papillomas to malignant SCCs (54).  A typical initiation-
promotion protocol using DMBA and TPA leads to the robust formation of both 
papillomas and SCCs.  The frequency of malignant conversion is dependent on many 
factors such as genetic background, dose of initiator and type of promoter used (54).  
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Figure 6. Multistage Carcinogenesis in Mouse Skin. The initiation-protocol protocol 
involves the application of a subcarcinogenic dose of a carcinogen (DMBA, MCA, 
MNNG) followed by repeated applications of a tumor promoter (TPA, UV, CHRY, 
wounding).  The model is divided into three distinct mechanistic stages: initiation, 
promotion and progression.  The initiation phase is characterized by an irreversible DNA 
damaging event in the target cells of the epidermis.  The second stage, promotion, 
involves repeated applications of a tumor promoter, which lead to the clonal expansion 
of initiated cells.  During the promotion stage, benign pre-malignant outgrowths called 
papillomas develop.  In the final stage, cells undergo further genetic alterations leading 
to increased genomic instability.  During this final stage, papillomas convert to invasive 
squamous cell carcinomas (SCC). Figure adapted from Abel et al. 2009 Nature 
Protocols.  
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1.13 Mechanisms of Skin Tumor Promotion 
While the initiation stage of mouse multi-stage skin carcinogenesis is 
relatively well understood in terms of molecular mechanism, the mechanisms 
underlying the promotion stage are less well defined. Tumor promotion is 
characterized by the development of a dramatic increase in epidermal cell 
proliferation and by significant dermal changes characterized by inflammation 
(58-62).  Processes altered during tumor promotion include increased DNA 
synthesis, increased ODC activity, increased growth factor production, altered 
redox status and increased prostaglandin synthesis [reviewed in (63)]. The 
effects observed during tumor promotion are largely due to promoter-induced 
alterations in gene expression and signaling molecules (58-60, 64, 65).  In 
general, many genes that encode growth regulatory molecules are up-regulated 
(mRNA and protein) or enzymatic activities are stimulated in response to 
exposure of mouse skin to tumor promoting stimuli (63, 66).  A number of 
changes in growth regulatory proteins and molecules occur during tumor 
promotion in the mouse skin model that are thought to stimulate a cascade of cell 
signaling events that alter cell proliferation and/or differentiation. Some of these 
proteins/molecules include: protein kinase C (PKC), EGFR, transforming growth 
factor alpha (TGF), transforming growth factor beta 1 (TGF); and 
prostaglandins.  Downstream mediators of these regulatory molecules include 
but are not limited to: protein kinase B (AKT), c-myc proto-oncogene (MYC), FBJ 
osteosarcoma oncogene (c-FOS), E2F transcription factor 1 (E2F-1), 
transformation related protein 63 (p63), mitogen activated protein kinase (MAPK), 
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phosphatidylinositol 3-kinase (PI3K), cyclin D1 (CCND1), and STAT3.   
For the phorbol ester type tumor promoters (includes TPA, teleocidins and 
aplysiatoxins) the cellular receptor that initiates their actions is PKC (67).  For 
compounds such as OA and calyculin A, the cellular receptors are protein 
phosphatases 1 and 2A (68). For many other skin tumor promoters, the 
existence of cellular receptors is not known and for compounds that break down 
to form reactive oxygen species and other types of radical intermediates such as 
the anthrones (e.g., anthralin, CHRY) and the organic peroxides [e.g., benzoyl 
peroxide (BzPo)] it is believed that they work by inducing oxidative stress that 
can activate multiple signaling pathways associated with skin tumor promotion 
(69).  
 
1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin or CHRY) is a prototypical 
anthrone derivative that represents a class of skin tumor promoters that work 
through a mechanism that is different than the phorbol esters.  CHRY does not 
directly interact with the PKC receptor suggesting that its activity is independent 
of the PKC signaling pathway (70). CHRY is very similar to another 9-anthrone 
derivative, anthralin.  Anthralin was first shown to be an effective tumor promoter 
by Bock and Burns in ICR Swiss mice over 40 years ago (Bock and Burns 1963) 
and subsequently CHRY was shown to be approximately 2-fold more active than 
anthralin when applied at equimolar doses (71).   Anthrones such as CHRY and 
anthralin undergo auto-oxidation in biological fluids producing reactive oxygen 
species and anthrone intermediate radicals.  Utilizing electron spin resonance, 
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anthralin has been shown to produce several oxidized products in mouse skin, 
including singlet oxygen and superoxide anion radicals (72, 73).   Structure-
activity studies for tumor promoting activity with anthrone derivatives have shown 
that oxidation at C10 of the molecule and subsequent generation of ROS is critical 
for their tumor promoter activity (74).  
Despite the known differences in mechanism between TPA and CHRY, 
both compounds cause several similar histological and biochemical alterations 
such as ornithine decarboxylase (ODC) induction and increased polyamine 
synthesis, increased epidermal DNA synthesis, edema, and hyperplasia following 
topical treatment.  ODC is the rate-limiting step in the synthesis of the 
polyamines.  At optimal promoting doses, induction of ODC and subsequent 
polyamine synthesis by CHRY exhibited differences in time course and 
magnitude compared to TPA (75, 76).  Epidermal DNA synthesis as well as 
epidermal hyperplasia of mice skin treated topically with CHRY exhibited a 
delayed peak compared to TPA (76) (77).  The results from these early studies 
has shown that hyperplasia produced in mice treated with TPA reached a 
maximum level at 48 hrs compared to mice treated with CHRY, which peaked at 
96 hrs following treatment.  Collectively, these findings have suggested that 
although TPA and CHRY ultimately produce similar effects (epidermal 
hyperproliferation, inflammation, and tumor promotion) their initial 
biochemical/molecular mechanism is different.  
1.14 Role of Inflammation in Cancer and Tumor Promotion 
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 Calor Dolor Rubor and Tumor translates to Heat, Pain, Redness and 
Swelling which represents the four classical signs of inflammation as was 
originally described by the First century encyclopedist Celsus AC., (Celsus AC., 
De medicina. Self published; A.D. 25).  The functional relationship between 
inflammation and cancer is not new. There is overwhelming experimental and 
epidemiological evidence that illustrates the importance of inflammation during 
the process of cancer development (78) .  Prostaglandin endoperoxide H 
synthases, also known as cyclooxygenase (Cox) is a key enzyme involved in this 
complex signaling cascade (79).  
 Cox enzymes catalyze the synthesis of prostaglandins from arachidonic 
acid (AA). Cox enzymes exist in predominately two major isoforms, Cox-1 and 
Cox-2.  Cox-1 is constitutively expressed in most cells and is responsible for 
tissue homeostasis, such as maintenance of gut mucosa and renal blood flow 
[reviewed in (80) ].  Cox-2, on the other hand, is an inducible protein that exists at 
low levels in mammalian cells devoid of stimulation.  Cox-2 can be activated by a 
variety of stimuli including bacterial endotoxins, cytokines, growth factors and 
hormones.  There is overwhelming evidence linking Cox-2 expression to the 
development of cancer.  Cox-2 has been shown to be overexpressed in various 
pre-malignant and malignant tissues, such as actinic keratosis/SCCs, 
adenoma/adenocarcinoma and bile duct hyperplasia/cholangiocarcinoma, 
[reviewed in (78)].   
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 There are also several lines of experimental data that support the role of 
Cox-2 in the process of tumorigenesis.  Female transgenic mice that overexpress 
Cox-2 in mammary tissue developed focal mammary gland hyperplasia, 
dysplasia and metastatic tumors (81).  Lastly, in addition to data from 
epidemiological and genetic studies, there are also numerous pharmacological 
studies that indicate that Cox-2 is a suitable therapeutic target.  Treatment with a 
selective Cox-2 inhibitor reduces the formation of tumors in inflammation-
associated malignancies such as intestinal (82), colon (83), bladder (84) , and 
skin tumors (85) in animals.   
 
 Growth factors, cytokines and tumor promoters stimulate Cox-2 expression 
by multiple signaling pathways including PKC and Ras-mediated signaling 
[reviewed in (78)].  Tumor promoters such as UV and TPA are known to induce 
Cox-2 expression in epidermis following exposure (86, 87).  It has been shown 
that both Cox isoforms have a role in keratinocyte differentiation. Utilizing the 
two-stage skin model, it was reported that tumor development in Cox-1 and Cox-
2 null mice were reduced compared to wild-type mice and was associated with 
premature keratinocyte differentiation (88).  Further studies have revealed that 
the impact of Cox-2 on epithelial tumorigenesis is context dependent.  
Transgenic mice that overexpress Cox-2 under the control of the keratin 14 
promoter (K14), referred to as K14.Cox-2 mice, were shown to be resistant to 
skin tumor formation using the two-stage model when TPA was used as the 
promoting agent.  The decrease in tumor development was attributed to reduced 
 27 
ODC induction, reduced interleukin-1α, and reduced TNFα in these K14.Cox-2 
mice.  In the same study, it was also shown that K14.Cox-2 transgenic mice 
when promoted with anthralin developed 6 times more tumors than control mice.  
Additionally, K14.Cox-2 mice treated only with DMBA developed 3.5 times more 
tumors compared to wild-type control mice (89).  Collectively, these results 
demonstrated the Cox-2 expression was important for epithelial tumor 
development and its role is context dependent.  
 
 The biological effects of Cox-2 induction are largely mediated via the 
actions of a class of signaling molecules called prostaglandins (PGs).  
Prostaglandins have several different isoforms that include PGE2, PGD2, PGI2, 
and PGF2.  PGE2 represents the most abundant isoform produced in the skin.  
PGE2 induces keratinocyte proliferation via multiple pathways including EGFR 
and PI3K (90).  PGs bind to four G-protein linked membrane receptors referred to 
EP1, EP2, EP3, and EP4 (91).  Mouse epidermis treated with TPA increase EP1 
and EP2 expression and both are upregulated in DMBA/TPA-induced papillomas 
and carcinomas (92).  Taken together these findings suggest Cox-2 expression 
and subsequent PGE2 induction are important signaling events in epithelial 
tumorigenesis.  
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Chapter 2: Rationale, Hypothesis and Specific Aims 
Rationale 
The primary goal of this research project is to understand the role of Stat1 
in multistage epithelial carcinogenesis and tumor promotion using the multistage 
mouse skin model.  Aberrant activation of STAT signaling has been associated 
with various pathological events, including cellular transformation and 
oncogenesis. Of all the STAT family members Stat1, 3 and 5 are most commonly 
associated with cell growth, proliferation, and apoptosis in cancer.  Previous work 
performed in our laboratory has established a critical role for Stat3 in epithelial 
tumorigenesis. However, the role of Stat1 in epithelial tumorigenesis has not 
been well defined.  Traditionally, Stat1 activity has been most commonly 
associated with anti-tumorigenic properties through modulating key components 
of immune tumor surveillance, inducing pro-apoptotic regulators such as 
Fas/FasL, caspases, and regulating cell cycle regulating genes as p21 and p27.  
Stat1 is also considered an indispensible upstream regulator of interferon 
signaling, as Stat1 deficient cells are unresponsive to both Type I and Type II 
interferons. The overall contribution of the IFNγ/Stat1 axis to the tumorigenic 
process is poorly understood and recent evidence suggests a pro-tumorigenic 
role for this pathway in several cancers.  
Recently, we have found that Stat1 is absolutely required for skin tumor 
promotion by the non-phorbol ester tumor promoter, CHRY, but not for tumor 
promotion by the classical phorbol ester tumor promoter, TPA. This requirement 
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for Stat1 in tumor promotion by CHRY involves IFNγ signaling and the induction 
of IRF-1 and unphosphorylated Stat1 (uStat1) in the epidermis.  
 
Hypothesis 
The hypothesis to be tested is that Stat1 plays a critical role in skin tumor 
promotion by CHRY but not TPA.  An additional hypothesis to be tested is 
that activation of Stat1 by CHRY occurs via IFNγ signaling. 
Specific Aims 
Specific Aim 1:  To determine the effect of treatment with mechanistically 
distinct tumor promoters on Stat1 activation in mouse epidermis.  In this 
aim, we evaluated STAT1 activation following treatment with diverse tumor 
promoting agents in dorsal mouse skin.  Utilizing Western blot analysis, we 
evaluated the activation status of Stat1 proteins following treatment with single 
and multiple applications of mechanistically distinct tumor promoters.  
Specific Aim 2: To determine the effect of Stat1 deficiency on epithelial 
tumorigenesis and investigate the underlying mechanism of CHRY-
mediated tumor promotion.  Utilizing the two-stage skin carcinogenesis model, 
we evaluated the impact of Stat1 deficiency on epithelial tumorigenesis using 
both TPA and CHRY.  In addition, we evaluated the impact of Stat1 deletion on 
short-term markers of tumorigenesis such as the proliferative response, 
apoptosis and differentiation. 
Specific Aim 3: To determine the role of IFNγ signaling in activation and up-
regulation of Stat1. In this aim, we investigated the IFNγ/Stat1/IRF-1 signaling 
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axis following multiple treatments with either TPA or CHRY. In addition, utilizing 
loss of function mouse models we also investigated the impact of Stat1 and 
IFNγR loss on interferon-mediated signaling following treatment with both CHRY 
and TPA. 
Specific Aim 4: To determine the role of IFNγ/pStat1/IRF-1 signaling on 
inflammatory signaling induced by CHRY. In this aim, we examined the 
impact of Stat1 deficiency on both TPA- and CHRY-mediated Cox-2 expression.  
The status of several other signaling pathways following topical application of 
either TPA or CHRY in both wild-type and Stat1 deficient (Stat1-/-) mice were also 
investigated. Utilizing Western blot and qPCR analysis, we evaluated the 
inflammatory response following treatment with both TPA and CHRY. 
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Chapter 3: Materials and Methods 
Animals, Antibodies, Chemicals and Reagents 
Animals 
Stat1-/- mice were a generous gift from Dr. David Levy (Kaplan Cancer Center, 
New York School of Medicine, New York, NY).  A functionally null Stat1 allele 
was generated by deleting a portion of the protein-coding region.  Using gene-
targeting techniques, 5.7 kb of genomic DNA was deleted.  The DNA that was 
excised contained three complete exons and a portion of a fourth that encode 
amino acids 221-365.  The deletion results in the loss of a portion of the DNA-
binding Domain (DBD), which produces a functionally inert protein (93). Stat1-/- 
knockout progeny were born at the expected frequencies from heterozygous 
mating, and exhibited no gross developmental abnormalities described by Durbin 
et al (93).   Even though Stat1 mice developed normally they were extremely 
sensitive to microbial challenge, (93, 94).  Stat1-/- mice were originally generated 
on a mixed C57Bl/6 genetic background. These mice were backcrossed for 5 
generations onto the FVB/N background.  Heterozygous (Stat+/-) mice were then 
mated to generate Stat1-/- and Stat1+/+ littermate control mice.  IFNγR1 deficient 
(IFNγR1-/- ) mice were purchased from The Jackson Laboratory (Bay Harbor, MA)
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Antibodies and Reagents  
Polyclonal rabbit anti-Cox-2 was purchased form Cayman Chemical Co. 
(Ann Arbor, MI); Rabbit anti-IRF-1 from Santa Cruz Biotechnology (Santa Cruz, 
CA) and Antibodies against phoshpo-Stat1 Y701, phospho-Stat1 S727 and total 
Stat1 were purchased Cell Signaling Technologies (Danvers, MA). 
Chemiluminescence detection kits were purchased from Pierce (Rockford, IL). 7, 
12 dimethylbenz(a)anthracene (DMBA), 5-bromo 2-deoxyuridine (Brdu), protease 
inhibitor cocktails, phosphatase inhibitor cocktails, mouse and rabbit secondary 
antibodies, and beta-actin were purchased form Sigma-Aldrich (St. Louis, MO). 
12-O-Tetradecanoylphorbol 13-acetate (TPA) was purchased from Alexis 
Biochemicals (Plymouth Meeting, PA).  Chrysarobin was synthesized in house 
from chrysaphanic acid as previously described (95)..  Mouse recombinant 
interferon gamma rIFNγwas purchased from BD Bioscience and used at 250 
ng/ml in primary cultures as previously described(96). 
 
Short-term promotion experiments  
For experiments were only Stat1 wild-type mice were used, female FVB/N 
mice (7-9 weeks of age) were purchased from the National Cancer Institute 
(Fredrick, MD) and group housed for the duration of the study in all experiments.  
In all other instances, Stat1-/- and Stat1+/+ mice were obtained from in house 
breeders as described above.  The dorsal skin was shaved 48 hrs prior to 
treatment with the indicated tumor promoter. Mice were treated with either 
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acetone vehicle (0.2 ml), TPA (3.4, 6.8, 13.6nmol) twice weekly for two weeks or 
with chrysarobin (100, 220, 440 nmol) once weekly for four weeks. Mice were 
sacrificed at the indicated time point(s) following the last treatment.   
For the analysis of epidermal proliferation and thickness, mice were 
injected intraperitoneal (i.p.) with 5-bromo-2'-deoxyuridine (BrdU) in PBS (100 
µg/g body weight) 30 min. prior to sacrifice. Excised dorsal skin sections were 
fixed in 10% neutral buffered formalin for 24-48 hrs and embedded in paraffin.  
Sections were either stained with, S100A8, K1, K5, K10, loricrin, K6, Hemotoxylin 
and eosin (H&E), anti-BrdU antibody or anti-caspase-3 by the histopathology 
core at UT MD Anderson Cancer Center-Smithville Science Park Division.  
Epidermal index was calculated as the percentage of BrdU positive cells; 600 
basal cells were counted from 3-4 skin sections for each mouse.  For epidermal 
thickness, 20 measurements were taken for each of 3-4 skin sections per mouse 
and the average thickness was calculated (97).  Apoptotic keratinocytes were 
counted microscopically and the index was calculated from the total number of 
caspase-3 positive basal cells in the entire skin sections from 3-4 individual mice 
from each group. 
 
Two-Stage Skin Carcinogenesis model 
Groups of 15-29 Stat1+/+ and Stat1-/- age matched females were used per 
group. Forty-eight hours prior to initiation the dorsal skin of was shaved. Mice 
were initiated with 25nmol DMBA dissolved in 0.2ml acetone. Two-weeks after 
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initiation mice received topical application of specified tumor promoter.  Due to 
mechanistic differences we used two different treatment regiments for promotion 
with TPA and CHRY. Two weeks after initiation, mice were treated topically with 
either 0.2ml acetone, 6.8nmol TPA, or 220nmol CHRY in 0.2 ml acetone.  Mice 
were treated twice weekly with TPA or treated once weekly with CHRY.  Mice 
received tumor promoter treatments until tumor multiplicity plateaued.  Tumor 
incidence (percentage of mice with papilloma) and tumor multiplicity (average 
number papilloma per mouse) was recorded weekly for the duration of the 
studies.   
 
Epidermal Lysate preparation 
After euthanization, the depilatory agent Nair was applied to the dorsal 
skin of mice for 30-45 sec and removed under running water. The skin was then 
excised and the epidermal layer was removed by scraping with a razor blade into 
chilled lysis buffer (1M Tris HCL pH 7.4, 3M NaCl, 0.5M EDTA pH 8.0, 10% 
Triton X-100, protease inhibitor, phosphatase inhibitor cocktail 1 and 2) and then 
homogenized using an 18-gauge needle. Epidermal lysates were centrifuged at 
14,000 RPM for 15min, and supernatant was collected. Protein concentration 
was determined and supernatant was snap frozen using liquid nitrogen and 
stored at -80°C until further analysis. 
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Adult Primary Keratinocyte Culture 
 
Primary mouse keratinocytes were isolated from 6-8 week old Stat1 wild-
type and Stat1-/- mice as previously described (98).  Briefly, mice were shaved, 
treated with a hair depilatory agent, after which dorsal skin was excised and 
floated on 0.25% trypsin for 4 hrs.  The epidermal cell layer was separated from 
dermis, minced and stirred in growth media supplemented with 10% fetal bovine 
serum for 30 min.  The cell suspension was filtered through a 70 m cell strainer.  
Cells were counted using a hemocytometer and plated on collagen coated plates 
and maintained in complete keratinocytes growth medium made up of Eagle's 
minimal essential base medium without Ca2+ supplemented as previously 
described (98).  Primary keratinoctyes were serum starved for 24 hrs prior to 
treatment. 
 
Western Blot Analysis  
Protein concentration was determined using Lowry protein assay 
according to manufacturer instructions. Fifty micrograms of protein lysate per 
lane was electrophoresed in 4-15% SDS-Page gradient gels and then transferred 
onto 0.45 um nitrocellulose membranes (BioRad, Hercules, CA). Membranes 
were blocked for 1 hour in 5% bovine serum albumin (BSA) in TBS with 0.1% 
tween (TBST) and incubated overnight at 4°C with specified primary antibody. 
The membranes were washed 3 times for 15 min each in TBST. Membranes 
were then incubated for 45 min in corresponding horseradish peroxidase-
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conjugated secondary antibodies in 3% non-fat dry milk (NFDM).  Membranes 
were then washed 3 times for 15 min. Protein bands were visualized using a 
chemiluminescence detection kit (Pierce ECL Western Blotting Substrate, 
Rockford, IL). Quantitation of total protein, and relative phosphorylation levels 
were calculated by densitometric analysis.  Actin was used to normalize protein 
loading and relative phosphorylation is calculated as a percentage of total protein. 
 
 mRNA analysis by Real-Time PCR.   
 Epidermal scrapings from the dorsal skin of sacrificed mice was submerge 
into RNA Later and placed at 4C for a minimal of 48 hrs. Total RNA was isolated 
by using the QIAGEN RNeasy RNA Isolation kits (74104) according to 
manufactures instructions.  First strand cDNA synthesis kit using random 
hexamer primers (Invitrogen) was used for cDNA preparation. SYBR Green was 
used for quantitative real-time PCR, which was performed on the Applied 
Biosystems RT-PCR system  (Applied Biosystems Viia 7).  Relative gene 
induction was calculated using Viia 7 software using the comparative Ct method 
(∆∆CT).   
 
Quantitation of Cytokines and Chemokines 
 RT2 Profiler PCR array mouse inflammatory cytokines and receptors 
(PAMN-011Z) (n = 4) were used to analyze the expression of a focused panel of 
genes. Data analysis was performed using the ∆∆CT method according to the 
manufacturer’s protocol (SABiosciences). 
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Prostaglandin E2 Assay 
Dorsal epidermis was chipped from frozen skin into ice-cold Eicosanoid 
Affinity Column Buffer (0.5 M phosphate solution, pH 7.0, containing 2.5 M 
sodium chloride and 0.25% sodium azide) containing 10 µmol indomethacin. 
After homogenization sample was centrifuged at 8,000X g for 10 min.  
Supernatant was collected.  Samples of mouse origin may contain antibodies, 
which interfere with the assay by binding to the goat anti-mouse plate.  Samples 
were purified prior to assay.  PGE2 was purified by passing clear supernatant 
through prostaglandin E2 affinity columns (Caymen chemical), the eluate was 
dried under a steady stream of nitrogen.  For assay, PGE2 was reconstituted in 
enzyme immunoassay (EIA) buffer (Cayman Chemical Company, Ann Arbor, MI) 
and assayed according to the manufacturer’s instruction. 
 
Statistical Analyses.  
 To compare epidermal thickness (µm) and labeling index (LI) (% BrdU 
positive cells) data were presented as the mean ± standard error of the mean 
(SEM).  For comparisons of epidermal thickness and LI, the Mann- Whitney U-
test was used (significance set at p≤0.05).  For comparison of tumor incidence 
the Chi-square (χ2) test was used (significance set at p≤0.05).  For comparison 
of tumor multiplicity data, the Mann-Whitney U-test was used (significance set at 
p≤0.05).  Statistical analysis was conducted using GraphPad Prism 4 software 
(San Diego, CA).
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Antibody List 
 
 
 
 
 
 
 
 
Antibody  Vender Catalog number 
Phospho-Stat1(Tyr701) Cell signaling  9171 
Phospho-Stat1 (Ser727) Cell Signaling  9177 
Stat1  Cell Signaling  9172 
Phospho-NF-κB (Ser536) Cell Signaling  3033 
NF-κB Cell Signaling 8242 
IRF-1 Santa Cruz Sc-640 
Actin Sigma Aldrich  A2066 
K5 Covance PRB-160P 
K10 Covance MMS-159S 
K1 Covance PRB-165P 
Loricrin Covance PRB-145P 
K6 Covance PRB-169P 
Cox-2 Caymen 160126 
Gene Forward Primer sequence Reverse Primer sequence  
Cox-2 CAAGACAGATCATAAGCGAGGA GGCGCAGTTTATGTTGTCTGT 
IRF-1 AATTCCAACCAAATCCCAGG AGGCATCCTTGTTGATGTCC 
IFNα TCCCTGTGCTGCGAGATCTTACTC CTGCTGCATCAGACAGGTTTGC 
IFNβ ACACTGCCTTTGCCATCCAAGAG TCCACCCAGTGCTGGAGAAATTG 
IFNγ CGAGATGACTTCGAAAAGCTG TCAGCCATCACTTGGATGAG   
Stat1 TCCCGTACAGATGTCCATGAT CTGAATATTTCCCTCCTGGG 
GAPDH TGTTCCAGAGACGGCCGCATCTTC AATGGCAGCCCTGGTGACCAGGC 
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Chapter 4: Effect of treatment with mechanistically distinct tumor promoters on 
Stat1 activation in mouse epidermis 
Rationale 
As stated in the introduction, STAT activation proceeds by a process of 
phosphorylation on conserved tyrosine and serine residues.  Phosphorylation of these 
conserved residues is critical for STAT transcriptional activity, but accumulating data 
has established a mechanism whereby uSTATs may also affect gene expression and 
contribute to the overall effects associated with this transcription factor.  In previous 
studies, it was shown that a variety of tumor promoters including the commonly used 
phorbol ester TPA, the phosphatase inhibitor okadaic acid, and the anthrone derivative 
CHRY activated epidermal STATs, following topical treatment.  All these tumor 
promoters were found to activate Stat3 in epidermis and in addition TPA was found to 
activate Stat1 and Stat5 (99).  The aim of this project was to further expand our 
knowledge of Stat1 activity/phosphorylation following treatment with various tumor 
promoters.  By utilizing mechanistically distinct tumor promoters the goal was to 
determine whether activation of Stat1 was a common mechanism in tumor promotion.   
 
 
 
4.1 Effect of a single topical application of mechanistically distinct tumor 
promoters on Stat1 activation in epidermis 
For these experiments, groups of 3-4 female FVB mice (6-8 weeks of age) 
received a single topical application with either acetone vehicle or 6.8 nmol TPA, 7.5 
 41 
nmol okadaic acid or 220 nmol CHRY.  Mice were sacrificed at the indicated time 
points and epidermal lysates were prepared as previously described. As shown in 
Figure 7, topical application of TPA caused an increase in Stat1 phosphorylation.  In 
this regard, following TPA treatment there was a significant increase in serine 727 
(S727) phosphorylation as early as 3 hrs, and phosphorylation remained elevated for at 
least 18 hrs following treatment.  Tyrosine phosphorylation of Stat1 was observed to be 
slightly elevated at 6 hrs following treatment. TPA treatment also resulted in an 
approximate 1.5 fold increase of total Stat1 protein 18 hours following treatment.  
Topical treatment with CHRY also led to an increase in phosphorylation of Stat1 on 
both tyrosine and serine residues compared to the acetone control group.  In addition, 
CHRY treatment also led to an approximate 2-fold increase in total Stat1 as early as 18 
hrs following treatment.  At the time points evaluated, there were no significant changes 
in Stat1 phosphorylation compared to the acetone controls following okadaic acid 
treatment.  These data suggested that activation/phosphorylation represents an early 
signaling event following topical treatment with both TPA and CHRY.  The increased 
tyrosine phosphorylation of Stat1 following both TPA and CHRY appeared to be due 
primarily to increases in Stat1 protein.  The increased phosphorylation of Stat1 on S727 
by CHRY also appeared to be due to increased Stat1 protein whereas TPA treatment 
led to a significant increased phosphorylation at S727 (see quantitation in Figure 7). 
Because the process of tumor promotion involves repeated treatments with tumor 
promoters, the next set of experiments involved using a multiple treatment regimen 
using both TPA and CHRY. 
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Figure 7.  Effect of a single topical application of TPA, CHRY, and okadaic acid 
on epidermal Stat1.  FVB mice (3-4/group) received a single topical application of 
either 6.8 nmol TPA, 7.5 nmol okadaic acid (OA), or 220 nmol CHRY in 0.2 ml 
acetone (Ace) and were sacrificed at the indicated timepoints. A) Mice were 
sacrificed at various time points and epidermal protein lysates were prepared for 
Western blot analysis using antibodies specific for the indicated proteins. B)  
Quantitation of total protein, normalized phospho-Stat1(S727) and normalized 
phospho-Stat1(Y701) were determined by densitometric analysis.  Actin was used to 
normalize protein loading and normalized phosphorylation is calculated as a 
percentage of total protein.  Values represent the average of three experiments ± 
SEM. 
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4.2 Effect of Multiple treatments with TPA and CHRY on Epidermal Stat1 
To better understand Stat1 signaling following tumor promoter treatment, 
we used a multiple treatment regimen for both TPA and CHRY and established a 
time course for Stat1 activation/phosphorylation.  Stat1-/- mice and wild-type 
controls were treated topically using a multiple treatment regimen involving 4 
treatments with either acetone, 6.8nmol TPA (2x/week for two weeks) or 
220nmol CHRY (1x/week for four weeks).  Mice were sacrificed at the specified 
time points and epidermal lysates were prepared for protein analysis by Western 
blot. 
 As shown in Figure 8, topical application with both TPA and CHRY induced 
rapid phosphorylation of epidermal Stat1 on both tyrosine (Y701) and serine 
(S727).   In this regard, phosphorylation at both Y701 and S727 occurred as 
early as 6 hrs following the last treatment with either promoter.  Phosphorylation 
at S727 persisted for up to 24-48 hrs after treatment whereas phosphorylation at 
Y701 was more transient.  During the course of these experiments, we observed 
that Stat1 protein levels were consistently increased at later time points following 
treatment with CHRY but not TPA (see again Figure 8) with a peak occurring 
approximately 48 hrs after treatment.  This increase in Stat1 protein level 
occurred at a time when little or no phosphorylation could be detected.  Thus, 
CHRY treatment led to the induction of uStat1.  To determine the mechanism for 
increased uStat1, we measured epidermal Stat1 mRNA levels following a single 
application of CHRY.  As shown in Figure 9, CHRY treatment led to a significant 
increase in Stat1 mRNA.  Thus, the increase in uStat1 protein was due to an 
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increase in Stat1 mRNA. As shown if Figure 9, Stat1 mRNA levels increased as 
early as 6 hrs (the earliest time point examined) and reached peak levels at 12 
hrs before returning to basal levels 24 hrs after treatment.  Collectively, the data 
in Figures 8 and 9, demonstrate that treatment with both tumor promoters led to 
rapid activation of Stat1 (i.e. phosphorylation on both tyrosine and serine 
residues).  However, only CHRY led to induction of uStat1. 
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Figure 8.  Effect of multiple topical applications with TPA and CHRY Stat1 on 
phosphorylation/activation.  Stat1 wild-type (Stat1+/+) or Stat1 Knock-out (Stat1-/-) 
mice received four topical applications of either 6.8 nmol TPA, or 220nmol CHRY in 
0.2 ml acetone (Ace). Epidermal lysates were collected for protein analysis by 
Western blot.  Mice were sacrificed at the indicated timepoints following last 
treatment and probed using antibodies specific for indicated protein. Quantitation of 
total protein levels was assessed by densitometric analysis.  Actin was used to 
normalize protein loading. A) Western blot analysis of Stat1 following topical 
application of TPA; B) Western blot analysis of Stat1 following topical application of 
CHRY. 
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Figure 9.  A single application of CHRY led to de novo synthesis of 
Stat1 mRNA. Wild-type (FVB) mice 6-8 weeks of age, received a single 
topical application of 220 nmol CHRY. Mice were sacrificed at the 
indicated time points for analysis of mRNA expression of Stat1 by RT-
PCR.  * Represents significant differences from acetone control (P-
value ≤ 0.05) 
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4.3 uStat1 is elevated and detected in nuclei of epidermal keratinocytes 
 As previously stated in the Introduction, STATs undergo cycles of 
cytoplasmic-nuclear shuttling.  Although uSTATs have been reported to shuttle 
between the nucleus and cytoplasm in un-stimulated cells the general consensus 
remains that STAT molecules require tyrosine phosphorylation for nuclear 
localization to induce subsequent gene expression (100).  Accumulating data has 
established a role for unphosphorylated STATs at the transcriptional level (39, 40, 
43).  To investigate whether uStat1 could affect transcription, we evaluated 
uStat1 nuclear localization.  As shown in Figure 10, uStat1 was elevated in 
epidermis as assessed by immunostaining at 48 hrs following treatment with 
CHRY.  Some nuclei appeared to be stained for uStat1.  Additional confocal 
microscopic analysis (Figure 11) revealed that following multiple applications of 
CHRY, uStat1 could be detected in the nuclei of keratinocytes 48 hrs after the 
last treatment.  It should be noted that there was no detectable phosphorylation 
of Stat1 at this time point (see again Figure 8).  These data confirm that CHRY 
treatment leads to upregulation of uStat1 and that uStat1 may have a function in 
regulating gene expression as has been recently proposed (39, 40, 42).
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Figure 10.  IHC analysis of Stat1 in mouse skin of Stat1wild-type and 
Stat1deficient mice following multiple treatments with CHRY.  Female 
FVB (3-4mice/group ) mice were treated with either acetone or 440nmol 
CHRY once weekly for four weeks and sacrificed 48hrs following final 
treatment. Skin sections were fixed in formalin, paraffin embedded, and 
immunostained for Stat1 alpha. 
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Figure 11.  Multiple applications of CHRY led to an increase in uStat1 
nuclear localization 48hrs after treatment.   Wild-type FVB mice received 
either acetone vehicle or 220nmol CHRY in 0.2 ml acetone (once weekly for 
four weeks).   Whole skin sections were excised, fixed in formalin and paraffin 
embedded.  Skin sections were immunostained with Stat1 and observed using 
confocal microscopy.  
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4.4 Topical application of α-Tocopherol acetate (αTA), inhibits epidermal 
proliferation and Stat1 Y701 phosphorylation by CHRY 
As noted in the Introduction, anthrones such as CHRY undergo auto-
oxidation to generate free radicals that are involved in their tumor promoting 
action.  Early studies from Fushs et al reported that treatment with the antioxidant 
α-tocopherol acetate (α-TA) inhibited ODC induction by anthralin, (72).  In early 
studies performed in our laboratory, it was shown that α-TA could partially block 
the effect of CHRY on EGF binding in vitro (101).  In addition, early studies by 
Battalora and DiGiovanni, (102) also showed that topical application of α-TA 
effectively inhibited CHRY mediated ODC induction, hyperplasia and tumor 
promotion.  The aim of this study was to evaluate the impact of α-TA on the 
epidermal proliferative response following treatment with CHRY and to evaluate 
its effect on CHRY-induced Stat1 Y701 phosphorylation.  For these experiments 
groups, of 3-4 female FVB mice received topical application of either acetone 
(vehicle), α-TA only, CHRY only or α-TA plus CHRY.  Antioxidant treatment was 
administered topically 5 min prior to receiving a topical dose of 220 nmol CHRY.  
α-TA treatment resulted in a decrease in the proliferative response as 
measured by both BrdU incorporation and epidermal thickness (Figure 12).  
Mouse skin pre-treated with 10 and 40 µmol of α-TA exhibited an approximate 
22% reduction in epidermal thickness compared to the CHRY treated group (46.4 
microns CHRY treated group versus 35.75 microns for both does of α-TA) 
(Figure 12).  α-TA treatment also led to a statistically significant reduction in 
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epidermal labeling index (LI) induced by CHRY (Figure 13).  Compared to the 
CHRY treated group, α-TA pretreatment resulted in an approximately 29% and 
23% decrease for 10 and 40 µmol, respectively (20.77% labeled in the CHRY 
treated group versus 14.74% and 15.94, respectively)(Figure 13). 
As shown in Figure 14, α-TA pretreatment reduced total Stat1 protein 
levels at 18 hrs after treatment with CHRY.  In this regard, α-TA pretreatment 
resulted in an approximate 1.6 and 1.3-fold (10 and 40 µmol) decrease in total 
Stat1 induction compared to the CHRY only treated group.  α-TA also caused an 
approximate 1.8 and 4.2-fold decrease in Y701 phosphorylation compared to the 
CHRY only treated group, at the 10 µmol and 40 µmol doses, respectively.  After 
normalization, α-TA effectively inhibited CHRY-mediated Stat1 Y701 
phosphorylation by decreasing Stat1 activation 3.0 and 8.3-fold (10 µmol and 40 
µmol doses, respectively) compared to the CHRY only treated group (see again 
Figure 14).  Collectively, these data indicate that the activation of Stat1 Y701 
phosphorylation requires the generation of free radicals from CHRY.   
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Figure 12.  Topical application of α-tocopherol caused a significant 
reduction in epidermal thickness. FVB mice (3-4/group) received a topical 
application of either acetone, α-TA only, or α-TA 5 min prior to receiving an 
application of 220 nmol CHRY in 0.2 ml acetone. Mice were treated once weekly 
for four weeks and sacrificed 18 hrs following final treatment.  Representative 
sections of whole skin were stained with hematoxylin are shown.  
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Figure 13.  Topical application of α-TA caused a significant reduction in 
BrdU incorporation.  FVB mice (3-4/group) received a topical application of 
either acetone, α-TA only, or α-TA 5 min prior to receiving an application of 220 
nmol CHRY in 0.2 ml acetone.  Mice were treated once weekly for four weeks 
and sacrificed 18 hrs following final treatment.  Representative sections of whole 
skin were stained with 5-bromo-2-deoxyuridine (Brdu) are shown.  
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Figure 14.  Topical application of α-tocopherol caused a significant 
reduction in Stat1 Y701 phosphorylation. FVB mice (3-4/group) received a 
topical application of either acetone, α-TA only, or α-TA 5 min. prior to 
receiving an application of 220 nmol CHRY in 0.2 ml acetone. Mice were 
sacrificed at 18 hrs after the last treatment with CHRY and epidermal protein 
lysates were prepared for Western blot analysis using antibodies specific for 
the indicated proteins Normalization performed by densitometric analysis. 
Actin was used to normalize protein loading and relative phosphorylation is 
calculated as a percentage of total protein. 
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Chapter 5: Stat1 is critical for CHRY Skin Tumor Promotion 
Rationale 
STATs are involved in many normal physiological processes but their aberrant 
activation has been associated with many pathological conditions including 
oncogenesis.  Previous work performed in our lab, demonstrated that Stat1 
phosphorylation was induced by TPA and was elevated in DMBA/TPA-induced 
papillomas compared to control skin, (99).  Furthermore, the data in Figures 8-11 
suggested the possibility that activated Stat1, including uStat1 may play a important 
role in skin tumor promotion by CHRY and that activated Stat1 may play a important 
role in skin tumor promotion by TPA.  To further explore this possibility, Stat1-/- mice 
(93) were used to evaluate their susceptibility to skin tumor promotion by both TPA and 
CHRY.   
5.1 Impact of Stat1 deletion on susceptibility to skin tumor promotion by TPA 
and CHRY 
To evaluate the impact of Stat1 deletion on skin tumor promotion by TPA and 
CHRY, groups of 19-29 mice for each genotype were used for two-stage skin 
carcinogenesis studies. The dorsal skin of mice was shaved 48 hours prior to initiation 
with DMBA.  All mice received topical application of 25 nmol of DMBA in 0.2 ml acetone 
to the shaved dorsal skin.  Two weeks after initiation, mice were treated topically with 
either 6.8 nmol TPA twice/weekly or 220 nmol CHRY once /weekly in 0.2 ml acetone.  
Mice were treated topically until tumor multiplicity reached a plateau.  The incidence of 
papillomas (percentage of mice with papillomas) and papilloma multiplicity (average 
number of papillomas per mouse) were tabulated and recorded weekly until the 
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papilloma response reached a plateau.  SCCs (both incidence and number) were 
recorded beginning at the time the first SCC appeared.  As shown in Figure 15, Stat1 
deficiency had no significant effect on skin tumor development when TPA was used as 
the promoting agent.  In this regard, there was no significant difference in formation of 
papillomas or SCCs in Stat1 deficient mice compared to wild-type controls.  By week 
23, Stat1 deficient mice had developed an average of 13.14 papillomas/mouse 
compared to 15.25 papillomas/mouse in the wild-type control group.  In addition, there 
were no observed differences in tumor latency between the two genotypes.  Both Stat1 
deficient mice and wild-type control mice reached 100% tumor incidence by week 10.  
Furthermore, there were no statistically significant differences observed in the 
malignant conversion between the two genotypes (Figure 15).   
 
In contrast to the results with TPA, mice deficient in Stat1, where highly resistant 
to papilloma development when CHRY was used as the promoting agent.  Stat1 
deficient mice developed far fewer papillomas compared to wild-type controls (Figure 
16).  By week 31, Stat1 deficient mice had only developed an average of only 0.16 
papillomas/mouse compared to 4.52 papillomas/mouse in the wild-type control group.  
Additionally, Stat1 deficient mice reached approximately 17% tumor incidence 
compared to 89% incidence in the wild-type control group.  At the time of study 
termination, the papillomas that developed in Stat1 deficient mice had not converted to 
squamous cell carcinomas, while Stat1 wild-type mice had 0.7 SCCs per mouse and an 
SCC incidence of 79%.  All SCCs were confirmed histologically in mice treated with 
both TPA and CHRY.  Due to the unusual findings with CHRY, a repeat two-stage skin 
carcinogenesis experiment was performed using groups of Stat1-/- (n=15) and wild-type 
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mice (n=19).  In this experiment, Stat1-/- mice again were highly resistant to skin tumor 
development with CHRY.  In this second experiment, wild-type mice had developed an 
average of 2.5 papillomas/mouse compared to 0.14 papillomas/mouse in the Stat1-/- 
group by week 29.  In addition, Stat1 wild-type mice had reached approximately 83% 
tumor incidence compared to 7.14% in the Stat1-/- group). 
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Figure 15.  Stat1 deficiency had no significant effect on tumor incidence and tumor 
multiplicity in the two-stage skin carcinogenesis model when TPA was used as the 
promoting agent.  Groups of mice of each genotype, (Stat1+/+or Stat1-/-) were initiated with 25 
nmol DMBA; two weeks after initiation mice were treated topically with 6.8nmol TPA twice per 
week until the tumor response reached a plateau; wild-type mice (n=29): Stat1-/- mice (n=24).  
A) Papilloma multiplicity and incidence B) Carcinoma multiplicity and incidence.  Significant 
differences in tumor incidence between groups were analyzed by Chi-square (χ2) and tumor 
multiplicity was analyzed by Mann-Whitney U. *(p < 0.05, Mann Whitney U). 
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Figure 16.  Stat1 deficiency resulted in a significant reduction in tumor incidence 
and tumor multiplicity in the two-stage skin carcinogenesis model when CHRY 
was used as the promoting agent.  Groups of mice of each genotype, (Stat1+/+or 
Stat1-/-) were initiated with 25 nmol DMBA; two weeks after initiation mice were treated 
topically with 6.8 with 220 nmol CHRY once per week until the tumor response reached 
a plateau. ; wild-type mice (n=24): Stat1-/- mice (n=19).    A) Papilloma multiplicity and 
incidence B) Carcinoma multiplicity and incidence. Significant differences in tumor 
incidence between groups were analyzed by Chi-square (χ2) and tumor multiplicity was 
analyzed by Mann-Whitney U. *(p < 0.05, Mann Whitney U). 
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5.2 Impact of Stat1 deletion on DMBA-induced epidermal apoptosis 
 
 To determine the impact of Stat1 deletion on epidermal apoptosis following 
treatment with DMBA, Stat1-/- mice and wild-type controls were treated with DMBA and 
the apoptotic response was evaluated by examining epidermal caspase-3 staining.  
Groups of 3-4 wild-type control and Stat1-/- mice were treated once topically with 
acetone vehicle or DMBA (200 nmol and 1000 nmol).  The apoptotic response was 
assessed by caspase-3 activation as described in the “Material and Methods” section.  
Topical application of DMBA resulted in an increase in caspase-3 positive cells in the 
epidermis compared to the acetone control, but there were no observable differences 
between the response in Stat1-/- mice and the wild-type control mice at either dose of 
DMBA (Figure 17).  These results confirmed that Stat1 does not play a significant role 
in survival of DNA damaged cells or apoptosis during initiation with DMBA.  These data 
also confirm that Stat1 plays a major role in tumor promotion by CHRY as indicated by 
the data in Figures 15 and 16.
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Figure 17.  Stat1 deficiency had no effect on epidermal apoptosis induced 
by DMBA. FVB mice (3-4 mice/group) 6-9 weeks of age received a single 
application of acetone, 200 nmol, or 1000 nmol of DMBA. Mice were sacrificed 
48hrs following treatment. Skin sections were collected and fixed in formalin and 
embedded in paraffin. Whole skin sections were stained with anti-caspase-3 and 
caspase-3 positive cells were accessed.  
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5.3 Impact of Stat1 deletion on epidermal hyperproliferation induced by TPA and 
CHRY 
 Earlier studies have established a good correlation between the tumor promoting 
ability of a compound with the induction of short term biomarkers such as induction of 
ODC, increase polyamine synthesis, inflammation and the ability to induce sustained 
epidermal hyperplasia (103).  To further explore the mechanism for the dramatic 
differences in response of Stat-/- mice to TPA vs CHRY, we examined the impact of 
Stat1 deficiency on epidermal hyperplasia by evaluating the proliferative response as 
measured by BrdU incorporation and epidermal thickness.  The proliferative response 
was evaluated after treatment with both tumor promoters.  Mice were again treated 
using a multiple treatment regimen and sacrificed 48 hrs following the last treatment.  
Epidermal thickness and LI were determined as previously described in the “Materials 
and Methods” section.  Stat1-/- and wild-type control mice were treated with either 
acetone vehicle or 3.4, 6.8, and 13.6 nmol TPA.  Following TPA treatment, there were 
no significant differences in BrdU incorporation or epidermal thickness at all doses 
tested between Stat1-/- and wild-type control mice. Figure 18 shows representative 
H&E and BrdU stained skin sections from TPA treated mice as well as quantitation of 
epidermal thickness and LI at all TPA doses tested.   
 
 A parallel study was conducted to evaluate the proliferative response following 
CHRY treatment.  Stat1 -/- and wild-type control mice were treated with either acetone 
vehicle or 110, 220, or 440 nmol CHRY using a multiple treatment regimen. Histological 
evaluation showed that Stat1-/- mice treated with CHRY displayed a reduced 
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proliferative response.  In this regard, Stat1-/- mice exhibited a reduced LI at all three 
doses of CHRY tested and reduced epidermal thickness at the highest dose tested 
(440 nmol).  Figure 19 displays representative H&E and BrdU stained skin sections 
from CHRY mice as well as quantitative analyses of both epidermal thickness and LI 
following treatment with CHRY.  
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Figure 18.  Stat1 deficiency had no significant effect on the epidermal 
proliferative response following topical application of TPA.  Wild-type 
(Stat1+/+) or knockout (Stat1-/-) mice received either acetone (vehicle) or TPA 
(3.4, 6.8, 13.6nmol) twice weekly for two weeks.  Forty-eights hours following 
the last treatment the dorsal skin sections were excised and fixed in formalin, 
embedded in paraffin, and then sectioned.  Sections were cut and stained with 
hematoxylin & eosin or anti-BrdU. Epidermal thickness and labeling index (LI) 
were determined as described previously. 
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Figure 19.  Stat1 deficiency resulted in a significant reduction in the 
epidermal proliferative response following topical application of CHRY.  
Wild-type (Stat1+/+) or knockout (Stat1-/-) mice received either acetone vehicle or 
CHRY (100, 220, 440nmol) once weekly for four weeks.  Forty-eights hours 
following the last treatment the dorsal skin sections were excised and fixed in 
formalin, embedded in paraffin, and then sectioned.  Sections were cut and 
stained with hematoxylin & eosin or anti-BrdU. Epidermal thickness and labeling 
index (LI) were determined as described previously. 
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5.4 Impact of Stat1 deletion on epidermal differentiation markers following 
treatment with CHRY. 
Epidermal differentiation plays an important role in the process of tumor 
development. Differentiation is characterized by quiescence at the G1 phase of the cell 
cycle (104) therefore differentiation represses the cells ability to respond to growth 
factors (105).  Based on the data that Stat1-/- mice were highly resistant to tumor 
formation by CHRY and the data in Figure 19 showing reduced proliferation, Stat1-/- 
mice were compared with wild-type mice for any changes in differentiation marker 
expression following treatment with this tumor promoter.  To evaluate epidermal 
differentiation, Stat1 wild-type and Stat1 -/- mice were treated once topically with 220 
nmol CHRY and sacrificed 18 hrs following treatment.  Whole skin sections were 
excised then fixed in formalin and paraffin embedded.  To assess keratinocyte 
differentiation we evaluated several common epidermal markers of differentiation 
including K5 (basal), K1 (suprabasal), K10 (suprabasal), loricrin (late state 
differentiation) and K6 (proliferation/hair follicle).  As shown in Figure 20, the absence 
of Stat1 did not appear to significantly affect expression of the selected differentiation 
markers following treatment with CHRY.
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Figure 20.  Stat1 deficiency had no significant effect on epidermal differentiation 
following topical application of CHRY compared to controls. Stat1 KO (Stat1-/-) mice 
and wild-type mice 6-8 weeks of age received either a single topical application of acetone 
or 220nmol CHRY in 0.2 ml. Mice were sacrificed at various time points and whole skin 
sections were prepared to assess epidermal differentiation.  Representative sections of 
whole skin sections stained with K5, K1, K10, Loricrin and K6 are shown.  
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Chapter 6 Role of IFNγ Signaling in Activation and upregulation of Stat1 
 
Rationale 
 Type I and II IFNs represent a class of pleiotropic cytokines with diverse functions 
that are context and cell specific.  IFNs play a vital role in the innate and humoral 
immune response to deal with invading pathogens.  IFNs are activated by a variety of 
stimuli and once activated they drive the expression of genes important for clearance of 
pathogens (e.g. IRF-1, OAS, iNOS).  The expression of IFNs in response to tumor 
promoter treatment is not well established.  The aim of this study was to examine IFN 
signaling following treatment with both TPA and CHRY and determine its role in 
activation of Stat1 observed following treatment with these promoters.   
 
6.1 Examination of IRF1 expression following treatment with diverse tumor 
promoters.   
In light of the data in Figure 8 showing induction of uStat1 following treatment of 
mouse epidermis with CHRY, we examined the status of IRF-1.  IRF-1 is an IFN-γ/p-
Stat1 responsive transcription factor that is known to regulate expression of a variety of 
genes, including uStat1 (106). Stat1-/- mice and wild-type controls were treated topically 
using a multiple treatment regimen involving 4 treatments with either acetone, 6.8 nmol 
TPA (2x/week for two weeks) or 220 nmol CHRY (1x/week for four weeks) as 
described above.  Mice were sacrificed at the specified time points and epidermal 
lysates were prepared for protein analysis by Western blot or RNA analysis by q-RT-
PCR as described in the Materials and Methods section.  As shown in Figure 21, IRF-1 
protein levels decreased in both wild-type and Stat1-/- epidermal lysates following TPA 
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treatment.  In addition, IRF-1 mRNA levels were not induced in response to TPA in 
epidermis of either genotype. On the other hand, CHRY treatment led to an increase in 
IRF-1 expression at both mRNA and protein levels (Figure 21B). Quantitation of IRF-1 
protein shows an approximate 3-fold increase of IRF-1 in wild-type controls as early as 
6 hours following treatment with CHRY.  Consistently, an increase in IRF-1 mRNA was 
observed by q-RT-PCR, peaking at 6 hrs and tapering off 24 hrs after treatment with 
CHRY.  Interestingly, Stat1-/- mice were highly resistant to IRF-1 induction by CHRY.  
Examination of epidermal lysates from Stat1-/- mice showed that loss of Stat1 
abrogated the induction of IRF-1 mRNA and protein following treatment with CHRY as 
observed in wild-type controls (panel B).   
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Figure 21. CHRY treatment led to an increase in IRF-1 expression, whereas TPA 
decreased IRF-1 levels. Wild-type (Stat1+/+) or knockout (Stat1-/-) mice received 
either A) TPA (6.8 nmol 2x/week for 2 weeks) or B) 220 nmol CHRY (1x/week for 4 
weeks) in 0.2 mL acetone (Ace). Mice were sacrificed at the indicated time points and 
epidermal lysates prepared for IRF-1 protein (Western blot) and mRNA expression 
(qPCR) analyses. Total protein levels were quantitated by densitometry. Actin was 
used to normalize protein loading. Western blot data are from a single experiment 
(pooled protein samples) that has been repeated with similar results. The mRNA data 
was obtained from individual mice (n=3-5/group) allowing statistical analysis.  * 
indicates values between Stat1+/+ and Stat1-/- groups were significantly different 
(Mann Whitney U, p≤0.05). 
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6.2 Examine the role of IFN signaling on Stat1 activation following treatment with 
TPA and CHRY.   
 
 The data shown in Figure 8 suggested that CHRY treatment influenced Stat1 
signaling via a different pathway than TPA, possibly involving IFNγ signaling. This was 
substantiated by examining IRF-1 status as shown in Figure 21. Collectively these data 
suggested that CHRY upregulated IFNγ signaling.  In light of these findings, we sought 
to determine how these two mechanistically different tumor promoters influence 
production of both Type I and II IFNs. Therefore, the expression of IFNα, IFNβ, and 
IFNγ was examined following treatment with both TPA and CHRY.  For these 
experiments, Stat1-/- and wild-type mice were again treated using a multiple treatment 
protocol as described above. As shown in Figure 22, TPA treatment did not induce 
epidermal IFNγ mRNA expression and, in fact, a statistically significant decrease was 
observed at all time points examined (panel A).   In contrast, a significant increase in 
IFNγ mRNA levels at 3, 6 and 12 hours after treatment with CHRY, with a peak at 
approximately 3 hrs after the last treatment (~8-fold increase compared to acetone 
treated control mice) (Figure 22 panel B).  Thus, induction of IFNγ was observed by 
treatment with CHRY but not following treatment with TPA.
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Next we wanted to examine the levels of Type I IFNs, to determine if they played a role 
in tumor promotion following tumor promoter treatment.  As shown in Figure 23, there 
were no significant increases in the Type I (α and β) IFNs following treatment with TPA 
and again like IFNγ the mRNAs for these two IFNs actually decreased after treatment.  
Following treatment with CHRY, there was a slight increase in IFNα mRNA at 6 hrs 
(p<0.05) but not at other time points and there were no increases seen in IFNβ mRNA.  
Collectively, these data indicate the Stat1 activation and upregulation of IRF-1 in 
epidermis is associated with significant upregulation of IFNγ mRNA and together these 
data demonstrate that CHRY activates IFNγ signaling whereas TPA does not. 
 
 Based on the data obtained in Figures 22 and 23, we hypothesized that CHRY-
mediated tumor promotion was dependent on a IFNγ/p-Stat1/IRF-1 signaling pathway, 
via induction of IFNγ ligand and activation of IFNγR1, whereas this pathway is not 
involved in skin tumor promotion by TPA.  To further test this hypothesis we employed 
the use of IFNγR1 knockout mice (IFNγR1-/-).  IFNγR1-/-and control mice were treated 
using a multiple treatment regimen as described above.  As shown in Figure 24, topical 
treatment with TPA did not induce IRF-1 mRNA in either wild-type or IFNγR1-/- mice.  In 
contrast, a significant increase in IRF-1 mRNA levels was observed in wild-type mice 
but not in IFNγR1-/- mice following treatment with CHRY.  Furthermore, topical 
treatment with TPA did not increase Stat1 mRNA levels in either wild-type or IFNγR1-/- 
mice.  However, CHRY treatment caused an approximate 2-fold increase in Stat1 
mRNA 24 hrs following treatment.  These data demonstrate that induction of IFNγin the 
epidermis by CHRY leads to induction of IRF-1 and uStat1 via signaling through 
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IFNγR1. 
To further validate our findings, we used Stat1-/- primary keratinocytes and recombinant 
mouse IFNγrIFNγas a surrogate for CHRY treatment in these cells.  Primary 
keratinocytes were harvested as described in the Material and Methods section and 
placed in starvation media for 24 hrs prior to stimulation.  As shown in Figure 25, 
treatment of wild-type keratinocytes with rIFNγand TPA increased phosphorylation of 
Stat1Y701 Phosphorylation of Stat1occured rapidly in response to rIFNγ treatment 
compared to TPA.  In addition, stimulation of primary keratinocytes with rIFNγ resulted 
in a significant increase in IRF-1 protein levels within 3 hours following treatment in 
wild-type, but not Stat1-/- keratinocytes.  In contrast, IRF-1 expression was unaffected 
in both wild-type and Stat1-/- keratinocytes, following treatment with TPA, in spite of 
increased phosphorylation of Stat1Y701 in wild-type keratinocytes.   In addition, we 
observed an increase in total Stat1 protein levels in rIFNγ but not TPA-treated wild-type 
keratinocytes.  These data confirm that keratinocytes respond to rIFNγ and TPA 
treatment in a manner similar to that observed in mouse epidermis in vivo and support 
the hypothesis that CHRY works via upregulation of the IFNγ signaling pathway. 
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Figure 22. CHRY treatment led to increased levels of IFNγ whereas 
TPA resulted in a decrease.  Wild-type mice 6-8 weeks of age received 
topical applications of acetone (Ace), TPA (6.8 nmol 2x/week for 2 weeks) 
or CHRY (220 nmol 1x/ week for 4 weeks). Mice were sacrificed at the 
indicated time points and epidermal mRNA expression was analyzed by 
qPCR. A) IFNγ mRNA levels following TPA and B) IFNγ mRNA levels 
following CHRY treatment  +indicates values significantly different from the 
Ace control;(Mann Whitney U, p≤0.05.  
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Figure 23. Following tumor promoter treatment Type I (α and β) Interferons 
levels decreased compared to acetone controls.  Wild-type mice 6-8 weeks of 
age received topical applications of acetone (Ace), TPA (6.8 nmol 2x/week for 2 
weeks) or CHRY (220 nmol 1x/ week for 4 weeks). Mice were sacrificed at the 
indicated time points and epidermal mRNA expression was analyzed by qPCR. A) 
Type I IFN mRNA levels following TPA treatment; B) Type I IFN mRNA levels 
following CHRY treatment * indicates values significantly different from the Ace 
control;(Mann Whitney U, p≤0.05).  
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Figure 24. CHRY treatment led to activation of the IFNγ-Stat1 signaling axis 
whereas TPA resulted in a decrease.  Wild-type and IFNγR1 knock-out mice 6-8 
weeks of age received topical applications of acetone (Ace), TPA (6.8 nmol 2x/week 
for 2 weeks) or CHRY (220 nmol 1x/ week for 4 weeks). Mice were sacrificed at the 
indicated time points and epidermal mRNA expression was analyzed by qPCR. A) 
IRF-1 mRNA levels following TPA and CHRY treatment; B) Stat1 mRNA levels 
following TPA and CHRY treatment. + indicates values significantly different from the 
Ace control; * indicates values between KO and wild-type mice were significantly 
different (Mann Whitney U, p≤0.05).  
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Figure 25.  Primary keratinocytes stimulated with IFNγ led to an induction of 
IRF-1.  Primary keratinocytes were isolated from Stat1 wild-type and Stat1-/- mice and 
cultured by methods described in the Material and Method section.  Primary 
keratinocytes were stimulated with either TPA (680 nM) or IFNγ (250ng/ml).  
Untreated cultured primary keratinocytes served as control.  Keratinocytes were 
stimulated for the indicated time point and harvested.  Protein lysates were prepared 
for Western Blot analysis.    
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Chapter 7.  IFNγ/pStat1/IRF-1 signaling axis regulates inflammation and 
inflammatory signaling induced by CHRY 
 
Rationale  
 As noted in the Introduction inflammation has long been associated with cancer 
development.  The JAK-STAT pathway is indispensible for innate as well as adaptive 
immunity, but persistent activation of these immunological response pathways may 
lead to chronic inflammation.  During a state of chronic inflammation in the skin, 
activated immunocytes are recruited to the area where they produce copious amounts 
of pro-inflammatory cytokines such as IL-6 [reviewed in (107)], TNFα [reviewed in(108) 
and IFNγ [reviewed in(109).  Based on the data presented in Chapters 5 and 6, a role 
for the IFNγ/pStat1/IRF-1 signaling axis in CHRY-mediated tumor promotion has been 
presented.  The aim of the studies in this chapter was to evaluate the potential role of 
this signaling pathway in inflammation and inflammatory signaling pathways associated 
with skin tumor promotion by CHRY.  For these studies we again used Stat1-/- mice. 
 
7.1.  Impact of Stat1 deficiency on NF-κB and Cox-2 following treatment with TPA 
and CHRY 
 
 To further explore potential mechanism(s) whereby IFNγ/pStat1/IRF-1 signaling 
mediates skin tumor promotion by CHRY, we examined the impact of Stat1 deficiency 
on NF-κB activation and Cox-2 expression following treatment with TPA and CHRY.  
For these experiments, wild-type and Stat1-/- mice were again treated using a multiple 
treatment protocol with either 6.8 nmol TPA or 220 nmol CHRY as described above.  
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Mice were sacrificed at the indicated time points following the last treatment.  
Epidermal lysates where collected for protein analysis by Western blot and analysis of 
mRNA by q-RT-PCR.  As shown in Figure 26, topical treatment with TPA led to an 
increase in Cox-2 expression (both mRNA and protein) as early as 6 hrs after the last 
treatment in both wild-type and Stat1-/- mice. In contrast, Stat1-/- mice exhibited a 
significant reduction in Cox-2 expression compared to the wild-type controls following 
treatment with CHRY.  In this regard, Stat1-/- mice exhibited an approximate 3-fold 
reduction in Cox-2 protein levels and an even greater reduction in Cox-2 mRNA at the 
12 hr time point compared to wild-type controls treated with CHRY (panel B).  The 
observed reduction in levels of Cox-2 in Stat1-/- mice persisted until levels reached 
baseline values at 48 hrs following treatment with CHRY.  Consistent with significant 
reductions in Cox-2 protein levels, Stat1-/- mice treated with CHRY exhibited a decrease 
in epidermal PGE2 levels compared to wild-type mice, whereas no differences in 
epidermal PGE2 levels were observed between the two genotypes treated with TPA 
(Figure 27).  Since NF-κB has previously been linked to Cox-2 expression in mouse 
epidermis, we evaluated whether the reduction in Cox-2 expression was associated 
with reduced NF-κB signaling after CHRY treatment.  Interestingly, activation of NF-κB 
signaling (measured by phosphorylation at Ser536) was similar in wild-type and Stat1-/- 
mice after treatment with CHRY.  As shown in Figure 26 panel C, the reduced 
expression of Cox-2 in epidermis of Stat1-/- mice seen following treatment with CHRY 
occurred in the presence of normal NF-κB signaling.
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Figure 26. Impact of Stat1 deficiency on the promoter-induced Cox-2 and NF-κB 
expression. Wild-type (Stat1+/+) or Stat1 knock-out (Stat1-/-) mice received 4 topical 
applications of either acetone (Ace), 6.8 nmol TPA, or 220 nmol CHRY and were 
sacrificed at the indicated time points. Epidermal lysates were prepared for protein 
analysis by Western blot and mRNA expression was examined by qPCR. Cox-2 
expression following A) TPA; and B) CHRY treatment; C) NF-κB signaling following 
CHRY treatment. Western blot data are from a single experiment (pooled protein 
samples) that has been repeated with very similar results. The mRNA data was 
obtained from individual mice (n=5/group) allowing statistical analyses.  * indicates 
values between Stat1+/+ and Stat1-/- groups were significantly different by Mann-
Whitney U (p≤0.05). 
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Figure 27.  Effect of Stat1 deficiency on prostaglandin E2 (PGE2) 
synthesis following tumor promoter treatment.  Wild-type (Stat1+/+) 
or knockout (Stat1-/-) mice received either a single 220 nmol dose of 
chrysarobin CHRY in 0.2 mL acetone (Ace) or four applications of TPA 
(6.8 nmol 2x/week for 2 weeks).  Following indicated time after last 
treatment the dorsal skin was excised and snap frozen with liquid 
nitrogen.  Pooled frozen epidermis from 3-4 mice was chipped into 
PGE2 lysis buffer.  PGE2 was eluted and assayed using manufacturer 
instructions.   
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7.2 Effect of Stat1 deficiency on iNOS expression and following topical treatment 
with TPA and CHRY.   
 iNOS is a Stat1 responsive gene that is responsible for the production of the 
reactive oxygen radical nitrous oxide (NO).  iNOS overproduction and the production of 
NO is associated with pathological conditions of inflammation (110) (111, 112) and 
tumor development (113). Therefore, we also determined the impact of Stat1 deficiency 
on the expression of iNOS in response to treatment with TPA and CHRY.  As shown in 
Figure 28 (panel A), topical treatment with TPA led to an increase in iNOS mRNA 
levels at 6 hrs, which quickly returned to basal levels at 18 hrs following treatment.  
Furthermore, no differences were observed in the response of Stat1-/- mice compared 
to wild-type control mice following treatment with TPA.  In contrast, treatment with 
CHRY led to a significant increase in iNOS mRNA levels in wild-type mice, but Stat1-/- 
mice where highly resistant to iNOS induction (Figure 28, panel B).  CHRY treatment 
led to a rapid increase in mRNA levels of iNOS as early as 6 hrs that remained 
elevated until iNOS reached basal levels at 48 hrs following treatment in wild-type mice.  
iNOS mRNA levels peaked around 12 hrs following treatment with CHRY: There was 
an approximate 10-fold increase in iNOS mRNA at this time point in wild-type 
compared to Stat1-/- mice.
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Figure 28.  Stat1 deficient mice were resistant to iNOS induction following 
CHRY treatment, whereas TPA-mediated induction of iNOS occurs 
independent of Stat1  Wild-type (Stat1+/+) or knockout (Stat1-/-) mice received 
either A) TPA (6.8 nmol 2x/week for 2 weeks) or B) 220 nmol CHRY (1x/week for 
4 weeks) in 0.2 mL acetone (Ace). Epidermal lysates were prepared at the 
indicated time points for mRNA analysis by qPCR.  The mRNA data was obtained 
from individual mice (n=3-5/group) allowing statistical analysis. * indicates value 
was significantly different from control (Mann Whitney U, p≤0.05). 
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7.3 Stat1 deficiency results in attenuated dermal infiltration of macrophages 
following treatment with CHRY 
Chronic inflammation is characterized by the infiltration of immunocytes.  This 
influx of immune cells represents a double-edge sword in that it has anti-tumorigenic as 
well as pro-tumorigenic effects.  As mentioned previously, Stat1 has been shown to be 
a vital player in the immune response, representing the major transducer of both Type 
1 and Type II IFNs.  Stat1 is rapidly activated in macrophages in response to treatment 
with lipopolysaccharide (LPS), a bacterial cell wall component that is a potent activator 
of immunocytes (114).  In addition, Stat1 regulates the expression of many 
chemoattractant chemokine/cytokines such as monokine induced by IFNγ (MIG), CC 
chemokine ligand-20 (CCL-20), epithelial cell- derived neutrophil-activating peptide 
(ENA-78) and IFN-inducible T cell-chemoattractant (I-TAC) (53). To examine the 
impact of Stat1 deletion on immune cell infiltration, Stat1-/- and wild-type control mice 
were evaluated for immune cell influx of various immunocytes by 
immunohistochemistry (leukocytes, mast cells, neutrophils, and macrophages).  
Groups of 3-4 mice of each genotype were treated once with 220 nmol CHRY and 
sacrificed at the indicated time points.  Qualitative immunohistochemistry studies 
revealed that Stat1 deficiency resulted in a decrease of macrophage infiltration into the 
dermal compartment of Stat1-/- mouse skin after treatment with CHRY compared to 
wild-type control mice (see Figure 29).  The differences in macrophage influx were 
most evident during the earlier time points examined (6 and 12 hour).  There were no 
noticeable differences seen in the infiltration of Tcells, mast cells or neutrophils (data 
not shown).     
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Figure 29.  Stat1 deficient mice displayed a reduced dermal inflammatory response (decreased macrophages) 
following topical application of CHRY compared to controls. Stat1 KO (Stat1-/-) mice and wild-type (Stat1+/+) mice 
6-8 weeks of age received either a single topical application of acetone or 220nmol CHRY in 0.2 ml. Mice were 
sacrificed at the indicated time points and whole skin sections were prepared to assess immune cell infiltration.  
Representative sections of whole skin sections were stained with S100A8 are shown. 
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7.4 Stat1 is necessary for expression of inflammatory chemokine/cytokines 
induced by CHRY  
Chemokines/cytokines play a vital role in tumor development.  Chronic 
inflammation promotes tumor development by inducing a cascade whereby both tumor 
cells and stromal cells produce various chemokines and cytokines [reviewed in (115, 
116)].  These various chemokines and cytokines may act in an autocrine or paracrine 
fashion to sustain tumor growth, induce angiogenesis, or facilitate evasion of immune 
surveillance by immunoediting.  Chemokines are classified into four groups, CXC, CC, 
CX3C and C, which is based on the positioning of the conserved two N-terminal 
cysteine residues (117).  To further evaluate the role of Stat1 in the production of 
chemokines and cytokines induced by CHRY, we utilized a real-time based 
inflammatory panel assay described in the Materials and Methods section and, mRNA 
isolated 6 hrs after the last of 4 treatments with CHRY.  As shown in Figure 30, the 
absence of Stat1 led to a significant reduction in expression of several inflammatory-
associated chemokines/cytokines (>2-fold) reduction compared to wild-type control 
mice following treatment with CHRY.  
 87 
  
Figure 30.  Stat1 deficiency caused a significant decrease in several inflammatory 
mediators following CHRY treatment.  Four to five Stat1+/+ (solid black) or Stat1-/- (white) 
mice received 4 topical applications of 220nmol CHRY and were sacrificed 6 hrs following 
the last treatment.  RNA was isolated from epidermal lysates as previously described in the 
Material and Methods section.  mRNA expression was analyzed by RT2  Profiler 
inflammatory cytokine/chemokine array (SA Bioscience) using manufacturer instructions.  
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Chapter 8: Ongoing and Future studies  
8.1 Stat1 and UV carcinogenesis  
In terms of human relevance, UV radiation (UVR) represents the major 
risk factor for skin cancer.  Acute exposure to UVR induces cell damage and 
induces DNA repair pathways.  Chronic exposure leads to increased epidermal 
damage, increased hyperplasia, and inflammation and skin cancer.  Skin cancer 
represents the most common cancer in humans today, with steadily increasing 
rates in new cases.  UVR is subdivided into UVA (315-400nm), UVB (290-
315nm) and UVC (100-280nm). The solar output that reaches the earth’s surface 
is approximately 95-98% UVA and 2-5% UVB, while UVC is completely absorbed 
by the stratospheric layer of the ozone. Although UVA is much more abundant, 
several studies have determined that wavelengths in the range of 295 nm to 
305nm (UVB) are the most important in influencing tumor development. 
[reviewed in(118)].  However UVA has been shown to posses both weak 
complete carcinogenicity and moderate skin tumor promotion ability [reviewed 
in(119)].  It should also be noted that solar radiation is more effective at inducing 
skin tumors in experimental animals than UVB alone further implicating a role for 
UVA in human skin cancer.    
 
Stat3 has been shown to play an important role in UVB-mediated skin 
carcinogenesis by modulating cell proliferation and apoptosis [reviewed in (118, 
120)].  In contrast, the role of Stat1 during UVB-mediated skin carcinogenesis 
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remains largely unknown.  Studies by Zhang et al report that following UVB 
irradiation, Stat1 is phosphorylated on its serine 727 residue, and not its Y701 
residue (121). As shown in Figure 31, preliminary data has confirmed that 
following a single exposure to 350 mJ/cm2 UVB, Stat1 S727 phosphorylation 
occurs as early as 3 hours in epidermis of FVB/N wild-type mice.  In contrast, 
there was no detectable phosphorylation of Stat1 on Tyr701 (see again Figure 
31).  Since serine phosphorylation is necessary for maximal transcriptional 
activity of STATs, it will be interesting to examine the transcriptional activity of 
Stat1 in the absence of tyrosine phosphorylation.  Studies are underway to fully 
characterize the role Stat1 in response to UVB irradiation.   
In addition to investigating UVB, we also plan to investigate UVA.  Data in 
the literature indicate that UVA exposure alone can induce skin papillomas and 
SCCs in mouse skin although with weaker activity that UVB (122).  Additional 
studies with UVA suggest that it produces biochemical and molecular changes in 
mouse skin similar to other types of tumor promoters (123) and that it possess 
tumor promoting activity in vivo (124).  A previous study reported that UVA (320-
400 nm) but not UVB (280-320 nm) irradiation of mouse skin led to the induction 
of IFNγ in epidermis of hairless mice (125).  Furthermore, low dose UVA 
irradiation of cultured human keratinocytes led to activation (DNA binding activity 
and tyrosine phosphorylation) of Stat1 (126).  These data suggest the possibility 
that UVA exposure may activate a similar signaling pathway involving IFNγ/Stat-
1/IRF-1 that may contribute to its tumor promoting activity.  Studies are currently 
underway to investigate the role of UVA irradiation on the IFNγ/pStat1/IRF-1 
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signaling axis.  For these experiments Stat1 wild-type and Stat1-/- will be 
irradiated with UV (UVA or UVB) and the impact of Stat1 deletion on signaling 
pathways, apoptosis, proliferation, and tumor development will be examined.
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Figure 31. Effect of UVB exposure on Stat1.  FVB/N wild-type mice 6-8 weeks of age 
were exposed to 350mJ/cm2 of UVB irradiation.  Mice were sacrificed at the indicated 
timepoint following irradiation.  Untreated mice served as the control.   Mice were 
sacrificed at the indicated time points and epidermal lysates were prepared for protein 
analysis by Western blot. 
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8.2 Possible role of IFNγ/pStat1/IRF-1 signaling in tumor promotion by other 
non-phorbol ester promoters 
Benzoyl Peroxide (BzPo) is an organic peroxide that is commonly used in 
cosmetic and pharmaceutical industries, in particular in the form of acne 
medication.  BzPo is another non-phorbol ester skin tumor promoter that forms 
radicals upon breakdown (69, 127).  The generation of such radicals is believed 
to be critical to its mechanism of skin tumor promoting action (128-130). BzPo 
induces short-term biomarkers commonly associated with tumor development 
such as ODC induction and increased epidermal hyperplasia,(131).  Thus, BzPo 
and CHRY share some similarities in this regard.  Preliminary data from our lab 
(see Figure 32), show that a single topical application of BzPo (20 mg/mouse) led 
to activation of Stat1 (phosphorylation at both Tyr701 and Ser727) at several time 
points after treatment.  In addition, Stat1 protein levels were significantly elevated 
at later time points (48, 72 and 96 hrs) after treatment.  These results are very 
similar to those obtained with CHRY suggesting that BzPo may work, at least in 
part through activation of the IFNγ/pStat1/IRF-1 signaling pathway.  We are 
currently determining the extent to which this pathway applies to the promoting 
action of BzPo and possibly other free radical generating skin tumor promoters.   
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Figure 32. Effect of BzPo treatment on Stat1 phosphorylation/induction 
in mouse epidermis. Wild-type FVB/N mice 6-8 weeks of age received a 
single application of acetone (Ace) or 20 mg BzPo. Mice were sacrificed at the 
indicated time points and epidermal lysates were prepared for protein analysis 
by Western blot. Protein levels were quantitated by densitometry.  Actin was 
used to normalize protein loading. phospho-Stat levels were normalized to 
total Stat1.    
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8.3 Cellular source of IFNγ production following treatment with CHRY  
As shown in Figure 22, treatment with CHRY caused a rapid increase in 
IFNγ mRNA in the epidermis.  At the present time we are unsure of the source of 
the IFNγ production.  Although keratinocytes express the IFNγ receptor it is not 
clear whether keratinocytes are capable of producing IFNγ.  The majority of IFNγ 
is produced by the activated immunocytes [reviewed in(132)].  Based on the 
findings that IFNγ mRNA is induced rapidly, it is likely that it is resident 
immunocytes of the epidermis.  Cells that reside in the epidermis include 
langerhans cells (LCs) and dendritic cells, especially γδ T cells(133).  γδ T cells 
are known to produce IFNγ (134) and it is possible that these cells or other 
resident T-cells are responsible for the increase in IFNγ mRNA seen in epidermal 
RNA samples following treatment with CHRY.  Utilizing flow cytometry methods, 
cells will be sorted based on immune subtype specific surface markers.  Once 
pure populations of the various cell types are acquired, the IFNγ production will 
be evaluated by intracellular cytokine staining.   
8.4 Studies using epidermis specific Stat1 deficient mice 
To date all experiments regarding Stat1 have been performed utilizing 
mice with deletion of Stat1 in all cells of the body (93).  Thus, some of the effects 
of Stat1 deletion on skin tumor promotion by CHRY could be due to loss of Stat1 
in other cells, e.g. immune/inflammatory cells.  Stat1-/- mice are known to have 
some defects in immune response (94) as well as defects in cytokine production 
(51).  In future studies, BK5.Cre x Stat1flox/flox mice will be used to evaluate the 
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impact of Stat1 deletion on epidermal proliferation and skin inflammation induced 
by CHRY.  Keratinocyte specific deletion of Stat1 will allow us to determine if the 
effects of Stat1 are cell autonomous to keratinocytes or are a result of the 
resident populations of immunocytes.  
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Chapter 9: Discussion 
 
In the current study, we examined the role of Stat1 in tumor promotion and 
epithelial carcinogenesis utilizing the well-established two-stage skin 
carcinogenesis model (54). The results demonstrate that topical application of 
both TPA and CHRY led to activation of Stat1 (phosphorylation at both Y701 and 
S727).  Furthermore, topical application of CHRY caused a significant increase in 
total uStat1 protein level whereas TPA did not.  Further mechanistic studies 
revealed that treatment with CHRY led to upregulation of signaling via IFNγ and 
that this was responsible for a significant portion of epidermal Stat1 activation as 
well as upregulation of uStat1 following treatment with this tumor promoter. 
Utilizing the two-stage skin carcinogenesis model, the importance of this 
signaling pathway in skin tumor promotion by CHRY was further demonstrated 
using Stat1-/- mice.  Stat1-/- mice were highly resistant to skin tumor promotion by 
CHRY but not TPA, indicating an absolute requirement for this pathway for tumor 
promotion by anthrone tumor promoters. Collectively, the current data 
demonstrate a novel mechanism of skin tumor promotion involving IFNγ-pStat1-
IRF-1 signaling and upregulaton of uStat1 in keratinocytes for the anthrone class 
of skin tumor promoters of which CHRY is the most potent member (135).  This 
pathway does not play a major role in skin tumor promotion by the phorbol ester, 
TPA.  
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In earlier studies from our laboratory, we reported that Stat1 activation 
(Y701 phosphorylation) along with Stat3 activation (Y705 phosphorylation) 
occurred in epidermis following topical treatment with TPA (99).  It was also 
shown that Stat1 phosphorylation was elevated in papillomas generated by a 
standard two-stage DMBA/TPA protocol (99).  The activation of Stat3 in 
keratinocytes was shown to be dependent on signaling through the EGFR 
although the mechanism for activation of Stat1 by TPA was not further 
investigated. As shown in Figure 8, treatment with both TPA and CHRY led to 
rapid activation of Stat1 in epidermis. However, treatment with CHRY also led to 
a significant upregulation of uSTAT1 suggesting that there might be fundamental 
differences in the mechanism of Stat1 activation between the two compounds.  
This hypothesis was borne out by further analyzing the potential role of IFNγ 
signaling following treatment with both types of promoters.  As noted in the 
introduction, a major pathway for activation of Stat1 in various cells, including 
keratinocytes, is via IFNγ receptor signaling (136, 137).  As shown in Figures 21 
and 24, treatment with CHRY but not TPA led to upregulation of IRF-1 and this 
was dependent on IFNγ receptor signaling via Stat1. 
 
The data in the current paper represent the first report that topical 
treatment with CHRY leads to upregulation of IFNγ and IFNγ-receptor signaling in 
epidermis.  The possible role of IFNγ in skin tumor promotion by TPA has 
previously been explored.  In earlier studies, Reiners and colleagues reported 
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that IFNγ could act as a co-promoter when injected i.p. together with topical 
application of TPA (138). IFNγ given alone did not promote skin tumors in mice 
initiated with DMBA in these earlier studies.  More recently, the role of IFNγ 
signaling in tumor promotion by TPA has been explored more directly using 
genetically engineered mouse models with conflicting results.  In this regard, 
Xiao et al reported that IFNγ mRNA levels were elevated in RNA samples 
isolated from whole skin following treatment with DMBA and either a single or 
multiple treatments with TPA (139).  In addition, these authors reported that Stat1 
was activated in protein lysates isolated from whole skin 24 hrs following the last 
TPA treatment.  These authors also reported that administration of an anti-IFNγ 
antibody or using of IFNγ receptor deficient mice reduced the number of 
papillomas but had no effect on the incidence of SCCs in a two-stage 
carcinogenesis protocol.  In contrast to these data, Wang et al (137) reported that 
IFNγ/- mice had nearly identical tumor response (both the percentage of mice 
with papillomas and papillomas per mouse) when compared with wild-type mice 
undergoing a two-stage (DMBA-TPA) protocol.  Our current data support the 
conclusion that IFNγ signaling via Stat1 and IRF-1 is not involved in skin tumor 
promotion by TPA.  However, the current data may explain the co-promoting 
effects if IFNγ as well as previous data showing that low doses of CHRY could 
also act as a co-promoter when given together with TPA (135). 
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As noted in the Introduction, several reports have indicated a possible pro-
tumorigenic role for Stat1 (45, 47, 140) although other studies have supported a 
tumor suppressor role for this signaling molecule. In a previous study, Schreiber 
et al. reported that following a single subcutaneous injection of the carcinogen 
methylcholanthrene (MCA), IFNγR-/- and Stat1-/- mice were highly susceptible to 
tumor formation compared to 129/Sv controls (141).  In this study they also report 
that Stat1 and p53 double knockout mice developed tumors more rapidly and 
with greater frequency then p53 single knockout, when challenged with MCA. 
Other studies have also shown that IFNγ plays an important role in immune 
surveillance for chemically-induced tumors, including skin tumors (141). In 
contrast, Hanada et al. (142) reported that mice deficient in Suppressor of 
Cytokine Signaling-1 (SOCS1), a negative regulator of STAT signaling, 
developed spontaneous colorectal carcinomas and their development was IFNγ-
dependent.  In this study, IFNγ-/-SOCS1-/- mice failed to develop tumors 
regardless of the upregulation of Stat3 responsive genes such as Bcl-XL and c-
myc when compared to the SOCS1-/- deficient mice. These results suggested a 
critical role for IFNγ/Stat1 signaling in the development of colorectal tumors in this 
mouse model. The current data clearly demonstrate an important role for Stat1 
activation via IFNγ signaling in epidermis in mediating skin tumor promotion by 
CHRY.  Perhaps Stat1 activation via IFNγ signaling has opposing roles during 
epithelial carcinogenesis in mouse skin: a pro-tumorigenic role during the early 
tumor promotion stage and an immune surveillance function once tumors are 
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developed.  Further ongoing studies using conditional Stat1 knockout mice will 
help to address these ideas in more detail. 
 
The mechanism(s) for how Stat1 mediates skin tumor promotion by CHRY 
remain to be fully determined. As shown in Figure 19, Stat1 deficient mice 
treated with CHRY had a reduced proliferative response as measured by BrdU 
incorporation and epidermal thickness. However, the decrease in epidermal 
proliferation seen in Stat-/- mice in response to treatment with CHRY did not 
appear sufficient to explain the dramatic inhibition of skin tumor promotion by 
CHRY seen in these mice (Figure 16). Stat1 has been shown to regulate the 
production of pro-inflammatory molecules such as inducible nitric oxide synthase 
(iNOS) and cyclooxygenase-2 (Cox-2)(52, 143). Furthermore, IFNγ is also known 
to upregulate a variety of inflammatory mediators including tumor necrosis factor 
alpha (TNFα) (144), interleukin-12 (IL-12) (145), gp91phox (146) and iNOS, (147). 
IRF-1 is a Stat1 responsive transcription factor that acts as a secondary 
response to activate other downstream targets (i.e., iNOS and Cox-2) (52, 148-
150).   As shown in Figure 21, treatment with CHRY also led to upregulation of 
IRF-1 that was blocked in both Stat1-/- and IFNγR1 -/- mice (Figures 21 and 24). 
Both TPA and CHRY treatment led to upregulation of epidermal Cox-2 
expression (both mRNA and protein) (Figure 26). Furthermore, the upregulation 
of Cox-2 (and PGE2) by CHRY but not TPA was dependent on activation of Stat1. 
Similar results were obtained for the upregulation of iNOS by both compounds 
(Figure 28).  The reduction in Cox-2 and iNOS expression in Stat1-/- mice 
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compared to wild-type mice following treatment with CHRY occurred in the 
presence of apparently normal activation of NF-κB (Figure 26, panel C) further 
demonstrating the importance of Stat1 signaling in mediating skin tumor 
promotion by CHRY. The induction of Cox-2 and the increased production of 
prostaglandins such as PGE2 represent important events in the process of skin 
tumor promotion (90, 151, 152). Therefore, Stat1/IRF-1 regulation of the 
induction of Cox-2 (and possibly iNOS) by CHRY may explain, at least in part, 
some of the mechanism associated with skin tumor promotion by this compound. 
 
Another interesting observation in the current study was the induction of 
uStat1 by CHRY but not TPA (Figure 8). Recently, it was found that Stats 1 and 3 
(and possibly other Stats) also play important roles in mediating gene expression 
in the absence of tyrosine phosphorylation (39, 40), Stat1 and Stat3 genes are 
targets of activated (phosphorylated) Stat1 and Stat3 proteins, respectively (41).  
As a result, cytokine activation of Stat1 or Stat3 (e.g., IFNγ or IL-6, respectively), 
leads to the induction and accumulation of uStats 1 and 3, which may persist for 
days after p-Stat levels have subsided (40). In addition, induction of the Stat1 
target gene, IRF-1, aids in the continued accumulation of uStat1 in response to 
IFNγ. It is well documented that uStats 1 and 3 can act as transcription factors 
and regulate a subset of genes that are different from those regulated by p-Stats 
(39, 42, 153). Together these data suggest that uStat1 may be transcriptionally 
active and play a significant role in skin tumor promotion by CHRY. 
Transcriptional profiling has shown that the majority of uStat1 target genes are 
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antiviral immune response genes, however uStat1 also induces a subset of 
genes implicated in radio- and chemo-resistance in cancer cells (42, 43). 
Disruption of interferon effector molecule 8 (IRF8) in soft tissue sarcoma cells 
leads to the accumulation of uStat1 (44) and promotes sarcoma cell metastasis 
by regulating gene transcription of apoptosis regulators Fas and Bad (44). 
However, the role and mechanism(s) by which uStat1 mediates a pro-
tumorigenic effect are largely unknown.  Future studies are aimed at defining the 
role of uStat1 in skin tumor promotion by CHRY and possibly other skin tumor 
promoters. 
 
An additional noteworthy aspect of the current studies involves the 
potential cellular source of epidermal IFNγ induced by treatment with CHRY.  
Although keratinocytes are known to express IFNγ receptors(154), there is little 
evidence in the literature suggesting that these cells produce IFNγ. Other cells 
that reside in the epidermis include Langerhans cells (LCs) and dendritic cells, 
especially γδT cells. γδT cells are known to produce IFNγ (155, 156) and it is 
possible that these cells or other resident or recruited T cells may be responsible 
for the increase in IFNγ mRNA seen in epidermal RNA samples following 
treatment with CHRY.  Ongoing studies are aimed at determining the cells in the 
epidermis responsible for production of IFNγduring tumor promotion by CHRY. 
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In conclusion, the current data identify a novel mechanism for skin tumor 
promotion involving activation of IFNγ signaling via p-Stat1 and IRF-1 that is 
required for the skin tumor promoting activity of CHRY, a member of the 
anthrone class of skin tumor promoters. This mechanism does not appear to play 
a major role in skin tumor promotion by the phorbol ester, TPA.  The 
mechanisms may involve the canonical pathway involving formation of p-Stat1 
homodimers, which lead to direct transcriptional regulation of IRF-1 and uStat1.  
Alternatively, or in addition, this could involve a non-canonical pathway involving 
the translocation of a complex containing IFNγR1-JAKS1/2-p-Stat1 to the nucleus 
where it binds to the IRF-1 promoter and induces transcription of IRF-1 (157, 
158). Upregulated IRF-1 then leads to increased transcription of a number of 
genes, including uStat1, iNOS and Cox-2 as well as others that ultimately 
contribute to the skin tumor promoting action of CHRY. Furthermore, both p-
Stat1 and IRF-1 have been shown to interact with NF-κB (159), and that may 
also play a role in altered expression of some genes.  Figure 33 proposes a 
working model for the role of IFNγ/p-Stat1/IRF-1 signaling in skin tumor 
promotion by CHRY encompassing these various aspects discussed above. 
 
The current data also support other emerging data in the literature that, 
under certain circumstances, Stat1 can have a pro-tumorigenic function. In this 
regard, the current studies demonstrate that Stat1 influences epithelial multistage 
carcinogenesis early during the process of tumor promotion with certain types of 
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chemical tumor promoters. The extent to which this mechanism applies to other 
types of chemical tumor promoters, especially those that work primarily through 
the generation of free radicals (e.g., BzPo) is currently under investigation.   
Further understanding of the downstream effectors of this novel skin tumor 
promotion pathway will aid in our understanding of the process of tumor 
promotion in general and in the identification of novel targets for cancer 
prevention.  
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Figure 33. Working Model For the Role of IFNγ/p-
Stat1/IRF-1 Signaling in Skin Tumor Promotion by CHRY 
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